

CURRICULUM VITAE Magnus Simrén 660218-5958

Name:	Jan Rune <u>Magnus Simrén</u>
Date of birth:	February 18, 1966
Citizenship:	Swedish
Education:	<ul style="list-style-type: none">* Medical school, University of Gothenburg, 1985-1991* Licence to practice 1993-08-01* Specialist in Internal Medicine 1998-08-31* Specialist in Gastroenterology and Hepatology 1999-09-02* PhD at the University of Gothenburg 2001-04-27; Thesis: "Irritable bowel syndrome – Pathophysiological and clinical aspects" (Supervisor: Einar Björnsson; Co-supervisor: Hasse Abrahamsson)* Post-doctoral research: Dept of Internal Medicine, Section of Gastroenterology (Professor Jan Tack), University Hospital Gasthuisberg, Katholieke Universiteit, Leuven, Belgium 2002* Associate Professor ("Docent") Internal Medicine and Gastroenterology 2004
Academic position:	Professor (associated prof ("adjungerad") 2009-2013; prof 2013-) Internal Medicine and Gastroenterology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 2009-
Previous positions:	<ul style="list-style-type: none">Internship 1991-1993 Lidköping County HospitalFellowship Internal Medicine and Gastroenterology and Hepatology 1993-1997 Lidköping County HospitalFellowship Gastroenterology and Hepatology 1998-1999 Sahlgrenska University Hospital, GöteborgSenior Researcher Swedish Research Council / University of Gothenburg in Molecular Gastroenterology (50%) 2011-2016Visiting research scientist Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States 2015-2016
Present position:	<ul style="list-style-type: none">Pro-Dean, Medical Faculty, Sahlgrenska Academy, University of Gothenburg 2024-2029Professor of Gastroenterology, University of Gothenburg 2013-Specialist (1999-) and Consultant (2004-) in Gastroenterology, Dept. of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, GöteborgUniversity Hospital Senior Consultant, Sahlgrenska University Hospital, Göteborg. 2010-Adjunct Professor of Medicine, University of North Carolina (UNC) School of Medicine, Chapel Hill, USA 2017-
Publications:	See publication list
Main research areas:	<ul style="list-style-type: none">* Functional GI disorders – symptoms, pathogenesis & pathophysiology, treatment, quality of life* GI motility disorders – treatment, diagnostics and pathophysiology* Quality of life in GI diseases* Brain-gut interactions in health and disease.* Food, microbiota and the GI tract in health and disease.* Link between inflammation, microbiology and GI symptoms.* Person centred care

Supervisor:

- *PhD student: Iris Posserud, MD ("Peripheral and central factors in the pathophysiology of IBS") – Thesis defended 2007-06-14
- *PhD student: Gisela Ringström, RN (Factors of importance for health care seeking in irritable bowel syndrome and the use of patient education) – Thesis defended 2008-12-04
- *PhD student Hans Strid, MD (Gastrointestinal symptoms in chronic renal failure) – co-supervisor; Thesis defended 2003-11-21
- *PhD student Evangelos Kalaitzakis, MD (The role of gut dysfunction and nutritional factors in liver cirrhosis) – co-supervisor; Thesis defended 2006-09-27
- *PhD student Stina Andersson, MD (Gastric electrical stimulation. Studies in patients with intractable nausea and vomiting) – co-supervisor; Thesis defended 2010-03-19
- *PhD student Perjohan Lindfors, MD (Implementation of gut-directed hypnotherapy for irritable bowel syndrome in clinical practice) – Thesis defended 2012-12-05
- *PhD student Eva Olausson, dietitian (Diagnosis & dietary intervention in patients with diabetic gastroparesis) – Thesis defended 2013-09-20
- *PhD student Lena Böhn, Dietitian (Importance of food items in patients with irritable bowel syndrome) – Thesis defended 2015-01-30
- *PhD student Börje Jonefjäll, MD (Gastrointestinal Symptoms and Fatigue in Patients with Quiescent Ulcerative Colitis) – co-supervisor; Thesis defended 2016-12-02
- *PhD student Ida Björkman, RN (A gender perspective on irritable bowel syndrome – Symptoms, patients' experiences and the development of a person-centred support intervention) – co-supervisor; Thesis defended 2016-12-08
- *PhD student Sean Bennet PhD (Immune function and microbiota alterations in IBS) – co-supervisor; Thesis defended 2017-12-15
- *PhD student Annikka Polster MD (Stratification and model-based analysis of patients with Irritable Bowel Syndrome using advanced biostatistics and medical data mining techniques); Thesis defended 2018-06-14
- *PhD student Cecilia Grinsvall, MD (Brain-gut interactions in irritable bowel syndrome (IBS) – supervisor. Thesis defended 2019-01-18
- *PhD student Egbert Clevers, PhD (Symptom patterns in irritable bowel syndrome.) – supervisor - Joint PhD with KU Leuven – Thesis defended 2019-11-14
- *PhD student Irina Midenfjord, Pharmacist (Irritable bowel syndrome – a disorder of gut-brain interaction) – supervisor. Thesis defended 2021-02-11
- *PhD student Sanna Nybacka, Dietitian (Managing irritable bowel syndrome: (Dietary approaches and food intolerance) - co-supervisor Thesis defended 2021-06-04
- *PhD student Jonas Varkey, MD (Intestinal transplantation: Outcome, complications and diagnostic approach) – supervisor. Thesis defense 2021-06-17
- *PhD student Georgios Mavroudis, MD (Mechanisms underlying inflammation, symptoms, and quality of life in ulcerative colitis) – co-supervisor. Thesis defended 2021-11-19
- *PhD student Cristina Iribarren PhD (Intestinal Microenvironment, epithelial barrier interactions and human milk oligosaccharides supplementation in irritable bowel syndrome) – co-supervisor. Thesis defended 2022-06-09
- *PhD student Luiza Gomes de Mello Moraes – MD (Molecular biosignatures and gut-barrier alterations in inflammatory bowel diseases) – co-supervisor. Thesis defended 2022-09-16

- *PhD student Åsa Frändemark, MD (Factors of importance for work productivity in irritable bowel syndrome) – supervisor. Thesis defended 2023-02-03
- *PhD student Esther Colomier, PhD (Dietary patterns linked to symptoms in patients with a disorder of gut-brain interaction) - syndrome) – Joint PhD with KU Leuven – supervisor. Thesis defended 2023-09-07
- *PhD student Cecilia Weznaver, Dietitian – (Carbohydrates and dietary interventions in IBS) – co-supervisor – Licentiate exam 2024-06-10
- *PhD student Joost Algera, MD (Food-related symptoms, dietary interventions, and importance of the gut microenvironment in IBS) – co-supervisor. Thesis defended 2024-09-27
- *PhD student Navkiran Tornkvist, MD (Characterization and impact of disorders of gut-brain interaction. A national and international epidemiological project) - co-supervisor. Thesis defended 2024-12-12
- *PhD student Nima Mottacki, MD (Bile acids in gastrointestinal diseases) - supervisor
- *PhD student Jessica Sjölund, MD (IBS: Painful Functional Gastrointestinal Disorders From Birth to Young Adulthood) – supervisor
- *PhD student Jenny Lövdahl, RN (Nurse-led gut-directed hypnotherapy in IBS) – supervisor
- *PhD student Antonios Kelepouris, MD (Diet and inflammatory bowel disease (IBD) - supervisor
- *Lujain Maasfeh, PhD (Clinical, Microbiologic and Immunologic Factors behind non-classical food allergy in patients with irritable bowel syndrome) – supervisor
- *Amanda Blomsten, MD (Diet and gut microbiota in the pathophysiology and treatment of irritable bowel syndrome (IBS) - Supervisor
- *PhD student Valeria Castro Tejera, MD (Inflammation in IBS) – co-supervisor
- * Research Fellow Apostolos Poulakis, MD (Combined multichannel impedance and pH measurement in the evaluation of Gastroesophageal reflux disease) 2008-2012
- Medical Student Mahrukh Khadija (IBS and comorbid conditions) 2023-
- *Medical student Janita Hamlinen (Functional GI disorders in patients with obesity) 2019-2021
- *Medical student Marcus Mujanovic (Irritable Bowel Syndrome - A descriptive study of symptom variation) 2018
- *Medical student Joost P Algera, Amsterdam (Efficacy of Gluten Free Diet on Visceral Sensitivity in Patients with Irritable Bowel Syndrome and Healthy Individuals) 2018-2019
- *Biomedical student Esther Colomier, Leuven, Belgium (Dietary pattern in IBS) Master thesis in Biomedical sciences 2018-2019
- *Medical student Amanda Rosendahl (Evolution of visceral hypersensitivity in IBS) 2015
- *Medical student Mathilda Mybeck (Atopy and IBS) 2015
- *Medical student Jakob Rasmussen (Visceral hypersensitivity in IBS) 2014
- *Medical student Sophie Hallberg (Dietary intake in patients with IBS) 2014
- *Medical student Axel Friis-Liby (Acute abdominal pain in the ER) 2014-2015
- *Medical student Kevin Afshari (Immunological alterations in IBS) 2009-2010
- *Medical student Katarina Wilpart (Pathophysiology of IBS) 2009-

- *Medical student Veronica Gunterberg (Autonomic nervous function in gastrointestinal diseases) 2010-2014
- *Medical student Emma Peterson (Evaluation of Short Health Scale in patients with IBS) 2011-2012
- *Medical student Alma Syrous (Good and bad bacteria in IBS)
- *Medical student Jonatan Tillander (Effects of nutrients on GI motility and sensation)
- *Medical student Lina Lönnström (Pathophysiology of IBS – impact of inflammation)
- *Medical student Amanda Ersryd (Link between pathophysiology and symptoms in IBS)
- *Medical student Johan Forshammar (GI Inflammatory changes in IBS)
- *Pharmacy Student Irina Midenfjord (Aloe Vera treatment for patients with irritable bowel syndrome)
- *Clinical supervisor: Andreas Pischel, MD – Specialist in Internal Medicine 2007; Specialist in Gastroenterology & Hepatology 2008
- *Clinical supervisor: Björn Lindkvist, MD - Specialist in Internal Medicine 2011
- *Clinical Supervisor: Karolina Sjöberg, MD; Specialist in Internal Medicine 2012
- *PostDoc: Hans Törnblom, MD, PhD from Karolinska Institute 2010–2012
- *PostDoc: Ola Olén, MD, PhD from Karolinska Institute 2010–2013
- *PostDoc: Anne Lund Krarup, MD from Aarhus, Denmark 2013
- *PostDoc: Stine Störsrud, Dietician, PhD from University of Gothenburg 2012-2018
- *PostDoc: Sofie Jacobsson, RN, PhD from University of Gothenburg 2013-2015
- *PostDoc: Antal Bajor, MD, PhD from University of Gothenburg 2013-2016
- *PostDoc: Johanna Sundin, PhD from Örebro University 2015-2018
- * PostDoc: Axel Josefsson, MD, PhD from University of Gothenburg 2015-2020
- * PostDoc Imran Aziz, MD, PhD from University of Sheffield, UK 2016-2018
- * PostDoc Sofia Nordlander, PhD from University of Oxford, UK 2017-2019
- * PostDoc Chloé Melchior, MD, PhD from University of Rouen, France 2020-2022
- * PostDoc Johann Pall Hreinsson, MD, PhD from University of Reykavijk, Iceland 2020-2023
- * PostDoc Piyush Patel, PhD from University of Gothenburg, 2020-2023
- * PostDoc Elias Ordell Sundelin, MD, PhD from Aarhus University Denmark 2020-2023
- * PostDoc Ines A Trindade, PsyD, PhD from University of Coimbra, Portugal, 2021-2023
- * PostDoc Sanna Nybacka, Dietitian, PhD from University of Gothenburg, 2021-2024
- * PostDoc Irina Midenfjord, PhD from University of Gothenburg, 2021-
- * PostDoc Anandi Rajan, PhD from University of Umeå (co-supervisor with Thaher Pelaseyed), 2021-2023
- *PostDoc Tom Van Gils, MD from Amsterdam University, 2023-
- * PostDoc Bani Ahluwalia, PhD from University of Gothenburg and Calmino AB 2023-2024
- * Wilhelm Sjöland, PhD from University of Gothenburg 2024

- * PostDoc Abdulsalam Aliyu, MD from University of Nottingham, UK 2024-
- * PostDoc Ryo Katsumata, MD from Kawasaki University, Japan 2024-

- Board Memberships:**
- * Chairman Swedish Young Gastroenterologists (SYG) 1998-1999
 - * Member of the Steering Committee Scandinavian Association for Gastrointestinal Motility (SAGIM) 2002-2007
 - * President Scandinavian Association for Gastrointestinal Motility (SAGIM) 2003-2007
 - * Member of the Steering Committee European Society of Neurogastroenterology and Motility 2002-2012
 - * Scientific secretary Swedish Society of Gastroenterology 2005-2008 (Three year appointment)
 - * Council member "Magtarmfonden" 2008-2011 (Research foundation)
 - * Member of ASNEMGE (Association of National European and Mediterranean Societies of Gastroenterology) Council 2008-2011
 - * Member of United European Gastroenterology National Societies Committee 2011-2012
 - * Member of the Functional Brain Gut Research Group Council 2009-2010
 - * Member of the American Neurogastroenterology and Motility Society/ Functional Brain Gut Research Group Council 2010-2012
 - * Member of the United European Gastroenterology Scientific Committee 2010-2013
 - * Chair of the United European Gastroenterology Scientific Committee 2013-2017
 - * Secretary General United European Gastroenterology 2018-2021
 - * Member of the United European Gastroenterology Council 2013-2021
 - * Member of the Faculty Board at the Sahlgrenska Academy at University of Gothenburg (2018-2024).
 - * American Gastroenterological Association (AGA) Neurogastroenterology & Motility (NGM) Section Councilor 2022-

Other appointments & Honors:

- Associate Editor GUT with responsibility for GI motility and sensation 2005-2009 (Four-year appointment)
- Deputy Editor GUT 2008-2009
- Editor, clinical science: Neurogastroenterology and Motility 2012-2016
- International associate editor: American Journal of Gastroenterology 2018-2021
- Editorial Board Member: Gut 2004-2005, 2009-; Clinical and Experimental Gastroenterology 2008-; Frontiers in Enteric Neuroscience 2009-
- Member of the Journal Management Committee for Neurogastroenterology and Motility 2009-2012
- Chair Journal Management Committee UEG Journal 2018-2021
- Associate Editor, Gastroenterology 2022-
- Advisory Board member: Movetis NV, Almirall, Novartis, AstraZeneca, Danone, Succampo, Chr Hansen, Albireo, Boehringer-Ingelheim, Shire, Allergan, Nestlé, Menarini, Arena, Ironwood, Tillotts, Biocodex, Adnovate, Tillotts, Kyowa-Kirin, Atnahs Pharma, Renapharma.
- Chair Rome Foundation Working Team "The role of the intestinal microbiota in functional gastrointestinal disorders" 2010-2012

- Chair Rome Foundation Working Team “Overlap in Disorders of gut-brain interaction (DGBI)” 2021-
- Member of Board of Directors Rome Foundation 2011-
- Member of the Rome IV committee for Bowel Disorders 2012-2016.
- Member of the Rome IV committee for Centrally Mediated Disorders of GI Pain 2012-2016.
- Member of the Rome V committee for Bowel Disorders 2021-
- Member of the Rome V Questionnaire committee 2021-
- Review panel member Swedish Research Council – International post-docs 2012
- Review panel member Swedish Research Council – Endocrinology, gastroenterology and metabolism 2022
- Review panel - assessment of the Department of Clinical Medicine (IKM) at the Faculty of Health and Medical Sciences, University of Copenhagen, Denmark 2023
- Member of Evaluation committee professorship at the University of Copenhagen, Denmark in Gastroenterology and Hepatology 2024.
- Vice chair European Cooperation in Science and Technology (COST) network, *BMBS COST Action BM1106*, “The Genes in Irritable Bowel Syndrome Research Network Europe” (GENIEUR). 2012-2016
- International Committee Member of Chinese Society of Gastroenterology 2014-2017
- Rome Foundation Fellow 2013
- Research Director Rome Foundation Research Institute 2017
- Fellow of the American Gastroenterological Association (AGA) 2012
- David Wingate lecture July 24th 2014; Barts and The London School of Medicine and Dentistry at Queen Mary, University of London, the Wingate institute, UK: “The puzzle of IBS: Can it be solved?”
- Visiting research scientist Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States 2015-2016
- Charles F Code lecture Dec 16th 2015; Mayo Clinic, Rochester, MN, USA: “Recent advances in IBS research that have led to tailoring treatment for the multiple symptoms in IBS patients”
- Visiting Professor April 2016 University of Michigan, Ann Arbor, Michigan, USA
- Visiting Professor (2016 Comfort in Gastroenterology Named Professor) May 2016 Mayo Clinic, Rochester, MN, USA
- Visiting Professor September 2016 Haukeland University Hospital, Bergen, Norway
- Visiting Professor June 2017 Aalborg University Hospital, Denmark
- Visiting Professor August 2017 Izmir University, Turkey
- Member International Scientific Committee, Biocodex Microbiota Foundation 2020-
- Board Member Gut Microbiota For Health 2012-
- Pro-Dean, Sahlgrenska Academy, University of Gothenburg 2024-2029

Faculty opponent:

- * MD Jens Bröndum Frökjaer, Aalborg University, Denmark: “Visceral sensations in health and diabetes” 24/4 2006
- * MD Per Ola Vandvik Trondheim University, Norway: “IBS in Norway” 2/6-2006 (second opponent)
- * MD Susanna Walter, Linköping University, Sweden: ”Irritable Bowel Syndrome. Diagnostic symptom criteria and impact of rectal distensions on cortisol and electrodermal activity” 15/12 2006

- * MD Clinton Seng Onn Ng, University of Sydney, Australia: "Studies of the sensory and motor function of the descending colon and rectum in health, irritable bowel syndrome and spinal cord injury" March 2007 (member of evaluation committee)
- * MD Tessa Kilkens, Maastricht University, Holland: "Serotonin and integrated brain-gut function in irritable bowel syndrome" 7/12 2007 (member of evaluation committee)
- * MD Johan Axel Lunding, Bergen University, Norway, "Gastic accommodation studied with ultrasound and barostat", 22/1 2008 (first opponent)
- *MD Brecht Geeraerts. KU Leuven, Belgium, "Role of central mechanisms in the pathogenesis of gastrointestinal symptoms, September 2008 (Jury member).
- * External reviewer Postdoctoral position KU Leuven, Belgium; MD, PhD Kathleen Blondeau 2009 (Fonds Wetenschappelijk Onderzoek)
- *MD Dag Arne Lihaug Hoff, University of Bergen, Norway: "Esophageal pain sensation during bag distension – biomechanical or ischemic in origin?", 26/2 2010 (first opponent)
- *MD Andreas Munch, Linköping University, Sweden: "Collagenous Colitis. The influence of inflammation and bile acids on intestinal barrier function". 21/5 2010.
- * External reviewer Postdoctoral position KU Leuven, Belgium; MD, PhD Pieter Janssen 2011 (Fonds Wetenschappelijk Onderzoek)
- * MD Helene Helgeland, University of Oslo, Norway: "Functional abdominal pain in children and adolescents in a biopsychosocial perspective". 30/3 2011 (First opponent)
- * MD Kurt Hanevik, University of Bergen, Norway: "Post-giardiasis functional gastrointestinal disorders and chronic fatigue syndrome – clinical symptoms, inflammation and immune responses". 20/1 2012 (First opponent).
- * MD Luise Begtrup, University of Odense, Denmark: ""Irritable bowel syndrome. Management and treatment in primary care" 6/12 2013 (First opponent)
- * PhD Hanne Vanheel, KU Leuven, "Duodenal implications in the pathophysiology of functional dyspepsia", May 2014 (Jury member)
- * Nutritionist Reijo Laatikainen, University of Helsinki, Finland, "Grains and irritable bowel syndrome. Randomised controlled trials with low FODMAP rye and wheat bread" September 14, 2018 (faculty opponent)
- * PhD Javier Aguilera-Lizarraga, KU Leuven, Belgium, "The pathophysiology of visceral hypersensitivity and food-induced abdominal pain revisited: Novel opportunities for treatment, April 26, 2019 (Jury member)
- * PhD Gunnhild Sellevoll Hunskår, University of Bergen, Norway, "Extra-intestinal complications following acute giardiasis", May 12, 2022 (First opponent)
- * PhD Karen Van den Houte, KU Leuven, Belgium, "Irritable bowel syndrome and functional dyspepsia: The role of food as a trigger for symptoms and a therapeutic target.", November 22, 2022 (Jury member)

Awards/Grants:

- * Research scholarship Jansen Cilag 2001 (50,000 SEK)
- * Research grant AstraZeneca & Göteborg University 2004-2006 (600,000 SEK/year)
- * Research Grant AstraZeneca & Göteborg University 2007-2009 (2x300,000 SEK)
- * "Rising star in European Gastroenterology" ASNEMGE 2006
- * International Foundation for Functional Gastrointestinal Disorders Research Award 2007

- * Swedish Research Council "Clinical and pathophysiological studies of disorders of gastrointestinal motility and perception" (K2007-55X-13409-08-3) 2007-2009 (500,000 SEK/year)
- * Swedish Research Council "Clinical and pathophysiological studies of disorders of gastrointestinal motility and perception" 2010-2012 ((K2010-55X-13409-11-3) (1,050,000 SEK/year)
- * Swedish Research Council "Symptom generation in functional and inflammatory gastrointestinal diseases: From basic understanding to new treatment options." 2013-2017 ((K2013-55X-13409-11-3) (1,400,000 SEK/year)
- * Swedish Research Council "Personalized medicine for patients with irritable bowel syndrome (IBS): Abnormal CNS function, altered gut microenvironment, or both?" 2019-2021 (2018-02566) (800,000 SEK/year)
- * Swedish Research Council "Brachyspira and intestinal allergy-like immune reactions in patients with irritable bowel syndrome." 2022-2025 (2021-00947) (1,300,000 SEK/year)
- *ALF, University of Gothenburg "Clinical and pathophysiological aspects of functional gastrointestinal disorders" 2005-2007 (ALFGBG2915) (400,000 SEK/year)
- *ALF, University of Gothenburg "Clinical and pathophysiological aspects of functional gastrointestinal disorders" 2008-2010 (ALFGBG-11259) (1,262,000 SEK/year)
- *ALF, University of Gothenburg "Mechanisms behind symptoms in functional and inflammatory gastrointestinal diseases" 2011-2014 (ALFGBG-143581) (1,475,000 SEK/year)
- *ALF, University of Gothenburg "Combining person-centered care and personalized medicine for patients with irritable bowel syndrome (IBS): A paradigm shift founded on multidisciplinary translational research. 2015-2017 (ALFGBG 438151) (1,975,000 SEK/year)
- *ALF, University of Gothenburg "Personalized medicine for patients with irritable bowel syndrome (IBS) based on multidisciplinary translational research findings. 2018-2021 (ALFGBG-722331) 2,000,000 SEK/year
- * ALF, University of Gothenburg "Brachyspira and intestinal allergy-like immune reactions in patients with irritable bowel syndrome." (ALFGBG-965173) 2022-2025 (2,000,000 SEK/year)
- * ALF, University of Göteborg ("Kombinationstjänst") 2013- (500,000 SEK/year)
- * ALF, University of Gothenburg ("Klinisk behandlingsforskning"); "Dietary interventions or pharmacological treatment to improve health in patients with irritable bowel syndrome (IBS) - a randomized, controlled trial." (ALFGBG-926581) 2020-2022, 800,000 SEK/year
- * ALF, University of Gothenburg ("Klinisk behandlingsforskning"); Dietary advice in irritable bowel syndrome (IBS) by internet-based group therapy – a project focusing on gastrointestinal symptoms, health economy, quality of life, and restrictive eating." (ALFGBG-978534) 2023-2025 1,000,000 SEK/year
- *Grant EU, Seventh Framework Programme – "Sensory and biomechanical markers in diabetic neuropathy of the gut. Investigations and new approaches for treatment. (with Aalborg & Aarhus, Denmark, Szent-Györgyi, Hungary and Diagles, Ireland) 2008-2011 (Grant no 223630) (1,800,000 €)
- *Grant Eurostars (EU/Vinnova): "Development of the Mucosal Patch Technology as a diagnostic test for detecting inflammation in the bowel of IBS patients" 2011-2014 (E! 5691 MucoMPO) (1,750,000 SEK)
- *EU Grant, Marie Curie Initial Training Network (ITN), FP7-People-2012-ITN: "European Training in Neural Regulation of Intestinal Function: NeuroGut"; Project number 607652 (with 10 other European research centres): (3,700,000 €) 2014-2018

- * Research grant for clinical research (80%) – Marianne and Marcus Wallenberg foundation 2010-2012 – (4,500,000 SEK)
- * Danone Clinical Research Grant 2010-2013 (500,000 €)
- * Research funding: Centre for person-centered care at Gothenburg University 2010: “Qualitative and quantitative aspects on symptom perception in patients with irritable bowel syndrome (IBS) – a person-centered approach” (1,230,000 SEK)
- * Research funding: Centre for person-centered care at Gothenburg University 2011-2013: “Qualitative and quantitative aspects on symptom perception in patients with irritable bowel syndrome (IBS) – a person-centered approach” 4,500,000 SEK
- * Research funding: Centre for person-centered care at Gothenburg University 2014-2015: “Qualitative and quantitative aspects on symptom perception in patients with irritable bowel syndrome (IBS) – a person-centered approach” 2,200,000 SEK
- * Research funding: Centre for person-centered care at Gothenburg University 2016: “Qualitative and quantitative aspects on symptom perception in patients with irritable bowel syndrome (IBS) – a person-centered approach” 1,000,000 SEK
- * Research funding: Centre for person-centered care at Gothenburg University 2013-2016: “Qualitative and quantitative aspects on symptom perception in patients with irritable bowel syndrome (IBS) – a person-centered approach” – 2 post-docs, 2 years: 3,600,000 SEK
- * Research funding: Centre for person-centered care at Gothenburg University 2011-2013: “Fatigue in chronic liver diseases” (1,500,000 SEK)
- * Research funding: Centre for person-centered care at Gothenburg University 2014-2015: “Fatigue in chronic liver diseases” (1,400,000 SEK)
- * Senior research position 50% “Molecular gastroenterology” Swedish Research Council 2011-2016 (2011-55P 21691-01-3) and Research Grant 1,000,000 SEK (2011-55X-21692-01-1) (Mechanisms behind functional and inflammatory gastrointestinal diseases).
- * Knut and Alice Wallenberg Foundation – “The mucus layer formed by the MUC2 mucin as the habitat of the colon commensal microbiota”. Total budget 3,075,000 € (One of six co-applicants) 2012-2016
- * AFA Försäkring – “Smärta hos patienter med irritable bowel syndrome (IBS): Från förståelse av mekanismer till utveckling av ny evidensbaserad behandling” 2015-2018 (6,771,000 SEK)
- * AFA Försäkring – ”Nedsatt arbetsförmåga hos personer med irritable bowel syndrome (IBS): Beror det på mag-tarm-symtom, muskuloskeletala symtom eller psykisk ohälsa?” 2019-2023, 4,750,000 SEK
- * Kostfonden & Skandia: “The role of carbohydrates in IBS” (PI: Stine Störsrud; Co-investigator M.Simrén). 2017-2023 2,940,000 SEK
- * Visiting research scientist Center for Functional GI and Motility Disorders, University of North Carolina, Chapel Hill, NC, United States 2015-2016. Grant support 100,000 \$
- * Swedish Research Council for Health, Working Life and Welfare (Forte) 2019-2021. “Kostbehandling för att förbättra hälsa hos patienter med irritable bowel syndrome (IBS)” (3,830,00SEK)
- * FRF-stiftelsen (Fonden för rehabilitering och medicinsk forskning) (Nedsatt arbetsförmåga hos personer med irritable bowel syndrome (IBS): Beror det på mag-tarm-symtom, muskuloskeletala symtom eller psykisk ohälsa?) 2019-2021, 1,000,000 SEK
- * Grant, EU, Horizon 2020 – DISCOvERIE "Development, diagnosis and prevention of gender-related Somatic and mental COmorbidiTiEs in iRritable bowel syndrome in Europe". 2020-2025 (Project no 848228) (6,000,000 € in total; 521,000 € to Gothenburg)

- * Familjen Erling-Perssons Stiftelse – “Irritable bowel syndrome (IBS): A disorder caused by microbes, leading to loss of tolerance to dietary antigens?”. 2020-2023 (9,000,000 SEK)
- * Unrestricted research grant BioGaia AB 2023-2026 – 5,550,000 SEK
- * PostDoctoral research collaboration, Calmino AB 2023-2024 – 500,000 SEK
- * Research Grant Sahlgrenska Academy (linked to position as Pro-Dean) 2024-2029 4,800,000 SEK
- * Familjen Kamprads Stiftelse (The Kamprad Family Foundation for Entrepreneurship, Research and Charity) – ”Skräddarsydd multidisciplinär internetbaserad behandling för att främja arbetsåtergång hos patienter med irritabel tarm (IBS) och multipla symtom” 2025-2027 – 3,000,000 SEK

GCP Training Principal Investigator and co-investigator in several clinical trials with GCP training included.

Publication list

Total number of articles: 329 peer-reviewed original articles (139 as first or last author); 90 peer-reviewed invited reviews (53 as first or last author); 30 editorials; 30 books/book chapters. Web of Science: total number of citations 23488, h-index 73. Google scholar: total number of citations 41615, h-index 98

Full papers

1. Simrén M, Castedal M, Svedlund J, Abrahamsson H, Björnsson ES. Abnormal propagation pattern of duodenal pressure waves in the irritable bowel syndrome (IBS). *Dig Dis Sci* 2000;45(11):2151-2161
2. Simrén M, Abrahamsson H, Björnsson, ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. *Gut* 2001;48(1):20-27
3. Simrén M, Månsson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. *Digestion* 2001;63:108-115
4. Simrén M, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in patients with the irritable bowel syndrome seen in referral centers versus primary care: The impact of gender and predominant bowel pattern. *Scand J Gastroenterol* 2001;36:545-552
5. Strid H, Norström M, Sjöberg J, Simrén M, Svedlund J, Abrahamsson H, Björnsson ES. The impact of sex, age and psychological factors on the water loading test in functional dyspepsia. *Scand J Gastroenterol* 2001;36:725-730
6. Simrén M, Axelsson J, Gillberg R, Abrahamsson H, Svedlund J, Björnsson ES. Quality of life in inflammatory bowel disease in remission: The impact of IBS-like symptoms and associated psychological factors. *Am J Gastroenterol*. 2002;97:389-396
7. Strid H, Simrén M, Svedlund J, Johansson AC, Samuelsson O, Björnsson E. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological well-being. *Nephrology Dial Transplant* 2002;17:1434-9

8. Johnsson F, Moum B, Vilien M, Grove O, Simrén M, Thoring M. On demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. *Scand J Gastroenterol* 2002;37:642-7
9. Simrén M. Physical activity and the gastrointestinal tract. (Leading article). *Eur J Gastroenterol Hepatol* 2002; 14:1053-1056.
10. Simrén M, Simms L, D'Souza D, Abrahamsson H, Björnsson ES. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. *Aliment Pharmacol Ther* 2003; 17:279-287
11. Simrén M, Stotzer P-O, Sjövall H, Abrahamsson H, Björnsson ES. Abnormal levels of neuropeptide Y and peptide YY in the colon in the irritable bowel syndrome (IBS). *Eur J Gastroenterol Hepatol* 2003;15:55-62
12. Strid H, Simrén M, Björnsson E. Overuse of acid suppressant drugs in patients with chronic renal failure. *Nephrology Dial Transplant* 2003;18:570-575
13. Simrén M. Quality of life in the irritable bowel syndrome: Measurement techniques and relevance of the current knowledge. *Expert Rev Pharmacoeconomics Outcomes Res* 2003; 3: 75-88
14. Simrén M, Silny J, Holloway R, Tack J, Janssens J, Sifrim D. Relevance of ineffective esophageal motility during esophageal acid clearance. *Gut* 2003; 52: 784-790.
15. Simrén M, Tack J. Functional dyspepsia: evaluation and treatment. *Gastroenterol Clin North Am.* 2003 ;32:577-99. Review
16. Gunnarsdottir A, Sadik R, Simrén M, Stotzer PO, Abrahamsson H, Olsson R, Björnsson ES. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis is associated with portal hypertension. *Am J Gastroenterol.* 2003 Jun;98(6):1362-70.
17. Simrén M, Vos R, Janssens J, Tack J. Acid infusion enhances duodenal mechanosensitivity in healthy subjects. *Am J Physiol Gastrointest Liver Physiol.* 2003 Aug;285(2):G309-15.
18. Strid H, Simrén M, Stotzer PO, Abrahamsson H, Björnsson E. Patients with chronic renal failure have abnormal small intestinal motility and a high prevalence of small intestinal bacterial overgrowth. *Digestion.* 2003;67(3):129-37.
19. Simrén M, Vos R, Janssens J, Tack J. Unsuppressed postprandial phasic contractility in the proximal stomach in Functional dyspepsia: Relevance to symptoms? *Am J Gastroenterol.* 2003 Oct;98(10):2169-75.
20. Björnsson E, Sjöberg J, Norström M, Simrén M, Abrahamsson H. Effects of duodenal lipids on gastric sensitivity and relaxation in patients with ulcer-like and dysmotility-like dyspepsia. *Digestion.* 2003;67(4):209-17.
21. Niklasson A, Bajor A, Bergendal L, Simrén M, Strid H, Björnsson E. Overuse of acid suppressive therapy in hospitalized patients with pulmonary diseases. *Respir Med.* 2003 Oct;97(10):1143-50.

22. Simrén M, Ringström G, Björnsson ES, Abrahamsson H. Treatment with hypnotherapy reduces the sensory and motor component of the gastrocolonic response in irritable bowel syndrome. *Psychosom Med*. 2004 Mar-Apr;66(2):233-8.
23. Ohlsson B, Ringström G, Abrahamsson H, Simrén M, Björnsson E. Oxytocin stimulates colonic motor activity in healthy women. *Neurogastroenterol Motil*. 2004 Apr;16(2):233-40.
24. Posserud I, Agerforz P, Ekman R, Björnsson E, Abrahamsson H, Simrén M. Altered visceral perceptual and neuroendocrine response in irritable bowel syndrome during mental stress. *Gut* 2004 Aug;53 (8):1102-1108.
25. Strid H, Simrén M, Björnsson E, Stotzer PO. Delay in gastric emptying in patients with chronic renal failure. *Scand J Gastroenterol* 2004;39(6):516-520
26. Simrén M, Brazier J, Coremans G, Dapoigny M, Müller-Lissner SA, Pace F, Smout AJPM, Stockbrügger RW, Vatn M, Whorwell PJ. Quality of life and illness costs in irritable bowel syndrome. *Digestion* 2004;69(4):254-61.
27. Björnsson E, Simrén M, Olsson R, Chapman R. Fatigue in patients with primary sclerosing cholangitis. *Scand J Gastroenterol* 2004;39(10):961-8
28. Simrén M, Björnsson E, Abrahamsson H. High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome. *Neurogastroenterol Motil* 2005;17(1):51-7.
29. Björnsson E, Simrén M, Olsson R, Chapman R. Fatigue is not a specific symptom of primary biliary cirrhosis. *Eur J Gastroenterol Hepatol* 2005;17(3):351-7
30. Simrén M. Alimentation et intestine irritable. *Hépato-Gastro* 2005;12:55-62
31. Olsson B, Truedsson M, Bengtsson M, Torstensson R, Sjölund K, Björnsson ES, Simrén M. Effects of a long-term treatment with oxytocin in chronic constipation; a double-blind, placebo-controlled pilot trial. *Neurogastroenterol Motil* 2005;17(5):697-704.
32. Törnblom H, Abrahamsson H, Barbara G, Hellström PM, Nyhlin H, Lindberg G, Ohlsson B, Simrén M, Sjölund K, Sjövall H, Schmidt PT, Öhman L: Swedish Motility Group. Inflammation as a cause of functional bowel disorders. *Scand J Gastroenterol* 2005;40(10):1140-8
33. Strid H, Simrén M. The effects of physical activity on the gastrointestinal tract. *International SportMed Journal* 2005;6(3):151-161
34. Björnsson E, Cederborg A, Åkvist A, Simrén M, Stotzer PO, Bjarnason I. Intestinal permeability and bacterial growth of the small bowel in patients with primary sclerosing cholangitis. *Scand J Gastroenterol* 2005;40(9):1090-4
35. Öhman L, Isaksson S, Lundgren A, Simrén M, Sjövall H. A controlled study of colonic immune activity and beta7+ blood T lymphocytes in patients with irritable bowel syndrome. *Clin Gastroenterol Hepatol*. 2005;3(10):980-6.
36. Simrén M. Hypnosis for irritable bowel syndrome: the quest for the mechanism of action. *Int J Clin Exp Hypn* 2006; 54(1):65-84

37. Lettesjö H, Hansson T, Peterson C, Ung KA, Ringström G, Abrahamsson H, Simrén M. Detection of inflammatory markers in stools from patients with irritable bowel syndrome and collagenous colitis. *Scand J Gastroenterol* 2006;41(1):54-9
38. Simrén M, Stotzer PO. Leading article: Use and abuse of hydrogen breath tests. *Gut* 2006;55:297-303
39. Simrén M, Svedlund J, Posserud I, Björnsson E, Abrahamsson H. Health-related quality of life in patients attending a gastroenterology outpatient clinic: functional disorders versus organic diseases. *Clin Gastroenterol Hepatol*. 2006 Feb;4(2):187-95. (*)
40. Posserud I, Ersryd A, Simrén M. Functional findings in irritable bowel syndrome. *World J Gastroenterol* 2006; 12(18):2814-2822.
41. Andersson S, Lönroth H, Simrén M, Ringström G, Elfvin A, Abrahamsson H. Gastric electrical stimulation (GES) for intractable vomiting in patients with chronic intestinal pseudoobstruction (CIP). *Neurogastroenterol Motil*. 2006 Sep;18(9):823-30.
42. Kalaitzakis E, Simrén M, Olsson R, Henfridsson P, Hugosson I, Bengtsson M, Björnsson E. Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. *Scand J Gastroenterol*. 2006 Dec;41(12):1464-72.
43. Nyblom H, Björnsson E, Simrén M, Aldenborg F, Almer S, Olsson R. The AST/ALT ratio as an indicator of cirrhosis in patients with PBC. *Liver Int*. 2006 Sep;26(7):840-5.
44. Björnsson E, Abrahamsson H, Simrén M, Mattsson N, Jensen C, Agerforz P, Kilander A. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. *Aliment Pharmacol Ther*. 2006 Sep 15;24(6):945-54.
45. Simrén M, Abrahamsson H, Björnsson ES. Lipid-Induced Colonic Hypersensitivity in the Irritable Bowel Syndrome: The Role of Bowel Habit, Sex, and Psychologic Factors. *Clin Gastroenterol Hepatol*. 2007 Feb;5(2):201-8.
46. Simrén M, Agerforz P, Björnsson ES, Abrahamsson H. Nutrient-dependent enhancement of rectal sensitivity in irritable bowel syndrome (IBS). *Neurogastroenterol Motil*. 2007 Jan;19(1):20-9.
47. Wallerstedt S, Olsson R, Simrén M, Broomé U, Wahlin S, Lööf L, Hultcrantz R, Sjöberg K, Gertzen HS, Prytz H, Almer S. Abdominal tenderness in ascites patients indicates spontaneous bacterial peritonitis. *Eur J Intern Med*. 2007 Jan;18(1):44-7.
48. Elfvin A, Amdersson S, Abrahamsson H, Edebo A, Simrén M, Lönroth H. Percutaneous implantation of gastric electrodes - a novel technique applied in animals and in patients. *Neurogastroenterol Motil*. 2007 Feb;19(2):103-9.
49. Holmén N, Isaksson S, Simrén M, Sjövall H, Öhman L. CD4(+)CD25(+) regulatory T cells in irritable bowel syndrome patients. *Neurogastroenterol Motil*. 2007 Feb;19(2):119-25.
50. Kalaitzakis E, Simrén M, Abrahamsson H, Björnsson E. Role of gastric sensorimotor dysfunction in gastrointestinal dysfunction and energy intake in liver cirrhosis. *Scand J Gastroenterol* 2007 Feb;42(2):237-46.

51. Öhman L, Simrén M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. *Dig Liv Dis* 2007 Mar; 39(3):201-15.
52. Posserud I, Stotzer PO, Björnsson ES, Abrahamsson H, Simrén M. Small intestinal bacterial overgrowth in irritable bowel syndrome. *Gut* 2007 Jun;56(6):802-8.
53. Simrén M, Abrahamsson H, Boseaus I, Brummer RJ, Dolk A, Lindberg G, Nyhlin H, Ohlsson B, Sjölund K, Törnblom H. Nutritional aspects in patients with functional gastrointestinal disorders and motor dysfunction in the gut. Working team report of the Swedish Motility Group (SMoG). *Dig Liv Dis* 2007 May;39(5):495-504.
54. Ersryd A, Posserud I, Abrahamsson H, Simrén M. Subtyping irritable bowel syndrome (IBS) by the predominant bowel habit: Rome II versus Rome III. *Aliment Pharmacol Ther* 2007 Sep 15;26(6):953-61.
55. Larsson MH, Simrén M, Thomas EA, Bornstein JC, Lindström E, Sjövall H. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. *Neurogastroenterol Motil.* 2007 Oct;19(10):812-20.
56. Ringström G, Strid H, Abrahamsson H, Simrén M. Why do not all subjects with Irritable Bowel Syndrome (IBS) seek Health Care for their symptoms? *Scand J Gastroenterol.* 2007 Oct;42(10):1194-203.
57. Posserud I, Syrous A, Lindström L, Tack J, Abrahamsson H, Simrén M. Altered rectal perception in irritable bowel syndrome is associated with symptom severity. *Gastroenterology.* 2007 Oct;133(4):1113-23.
58. Sadik R, Stotzer PO, Simrén M, Abrahamsson H. Gastrointestinal transit abnormalities are frequently detected in patients with unexplained GI symptoms at a tertiary centre. *Neurogastroenterol Motil.* 2008 Mar;20(3):197-205..
59. Niklasson A, Strid H, Simrén M, Engström CP, Björnsson E. Prevalence of Gastrointestinal Symptoms in Patients with Chronic Obstructive Pulmonary Disease. *Eur J Gastroenterol Hepatol* 2008 Apr;20(4):335-41.
60. Abrahamsson H, Löroth H, Simrén M. Progress in gastric electrical stimulation. *Gastrointest Endosc.* 2008 Jun;67(7):1209-10.
61. Simrén M, Svedlund J, Posserud I, Björnsson ES, Abrahamsson H. Predictors of subjective fatigue in chronic gastrointestinal disease. *Aliment Pharmacol Ther.* 2008 Sep 1;28(5):638-47.
62. Forshammar J, Isaksson S, Strid H, Stotzer PO, Sjövall H, Simrén M, Öhman L. A pilot study of colonic B cell pattern in irritable bowel syndrome. *Scand J Gastroenterol* 2008;43(12):1461-6.
63. Gunnarsson J, Simrén M. Efficient diagnosis of suspected functional bowel disorders. *Nat Clin Pract Gastroenterol Hepatol* 2008 Sep;5(9):498-507.
64. Schmidt PT, Abrahamsson H, Dolk A, Hausken T, Karling P, Lindberg G, Nyhlin H, Ohlsson B, Simrén M, Sjölund K, Stotzer PO, Törnblom H. Methods to assess gastric motility and sensation. *Scand J Gastroenterol* 2008;43(11):1285-95.

65. Abrahamsson H, Östlund-Lindqvist AM, Nilsson R, Simrén M, Gillberg PG. Altered bile acid metabolism in patients with constipation-predominant irritable bowel syndrome and functional constipation. *Scand J Gastroenterol*. 2008;43(12):1483-8.
66. Simrén M, Posserud I, Stotzer PO, Björnsson ES, Abrahamsson M. Authors' reply. *Gut* 2008;57:1335
67. Ringström G, Störsrud S, Lundqvist S, Westman B, Simrén M. Development of an educational intervention for patients with Irritable Bowel Syndrome (IBS) - a pilot study. *BMC Gastroenterol* 2009 Feb 4;9(1):10.
68. Strid H, Fjell A, Simrén M, Björnsson ES. The impact of dialysis on gastroesophageal reflux, dyspepsia and PPI treatment in patients with chronic renal failure. *Eur J Gastroenterol Hepatol* 2009 Feb;21(2):137-42.
69. Ringström G, Agerforz P, Lindh A, Jerlstad P, Wallin J, Simrén M. What do patients with irritable bowel syndrome know about their disorder and how do they use their knowledge? *Gastroenterol Nurs* 2009 Jul-Aug;32(4):284-92.
70. Posserud I, Svedlund J, Wallin J, Simrén M. Hypervigilance in the irritable bowel syndrome compared with organic gastrointestinal disease. *J Psychosom Res* 2009 May;66(5):399-405.
71. Öhman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M. B cell Activation in Patients with Irritable Bowel Syndrome (IBS). *Neurogastroenterol Motil* 2009 June (6); 21:644-650.
72. Öhman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M. T cell activation in patients with irritable bowel syndrome. *Am J Gastroenterol* 2009 May; 104(5):1205-12.
73. Simrén M. Bloating and abdominal distention: Not so poorly understood anymore! *Gastroenterology* 2009 May; 136(5):1487-90.
74. Bajor A, Ung KA, Öhman L, Simrén M, Thomas EA, Bornstein JC, Sjövall H. Indirect evidence for increased mechanosensitivity of jejunal secretomotor neurons in patients with idiopathic bile acid malabsorption. *Acta Physiol (Oxf)*. 2009 Oct;197(2):129-37.
75. Gunnarsson J, Simrén M. Peripheral factors in the pathophysiology of irritable bowel syndrome. *Dig Liv Dis* 2009 2009 Nov;41(11):788-93.
76. Simrén M. Altering the gastrointestinal flora in patients with functional bowel disorders: A way ahead? *Ther Adv Gastroenterol* 2009; 2, Suppl 1:S5-S8
77. Truedsson M, Carlson J, Simrén M, Ohlsson B. Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms. *BMC Gastroenterol*. 2009 Nov 30;9:90.
78. Sadik R, Björnsson E, Simrén M. The relationship between symptoms, body mass index, GI transit and stool frequency in patients with irritable bowel syndrome. *Eur J Gastroenterol hepatol* 2010 Jan;22(1):102-8.
79. Simrén M, Ohman L, Olsson J, Svensson U, Ohlson K, Posserud I, Strid H. Clinical trial: the effect of a fermented milk containing three probiotic bacteria in patients with irritable bowel

- syndrome (IBS) - a randomized, double-blind, controlled study. *Aliment Pharmacol Ther.* 2010 Jan;31(2):218-27
80. Ringström G, Störsrud S, Posserud I, Lundqvist S, Westman B, Simrén M. Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study. *Eur J Gastroenterol Hepatol.* 2010 Apr;22(4):420-8
81. Andersson S, Elfvin A, Ringström G, Lönroth H, Abrahamsson H, Simrén M. A slow caloric satiety drinking test in patients with temporary and permanent gastric electrical stimulation. *Eur J Gastroenterol Hepatol.* 2010 Aug;22(8):926-32.
82. Öhman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. *Nat Rev Gastroenterol Hepatol* 2010 Mar;7(3):163-73.
83. Niklasson A, Lindström L, Simrén M, Lindberg G, Björnsson E. Dyspeptic Symptom Development After Discontinuation of a Proton Pump Inhibitor: A Double-Blind Placebo-Controlled Trial. *Am J Gastroenterol.* 2010 Jul;105(7):1531-7.
84. Jerndal P, Ringström G, Agerforz P, Karpefors M, Akkermans LM, Bayati A, Simrén M. Gastrointestinal-specific anxiety: An important factor for severity of GI symptoms and quality of life in IBS. *Neurogastroenterol Motil.* 2010 Jun;22(6):646-e179.
85. Pedersen SMM, Nielsen NC, Andersen HJ, Olsson J, Simrén M, Öhman L, Svensson U, Malmendal A, Bertram HC. The Serum Metabolite Response to Diet Intervention with Probiotic Acidified Milk in Irritable Bowel Syndrome Patients Is Indistinguishable from that of Non-Probiotic Acidified Milk by ¹H NMR-Based Metabonomic Analysis. *Nutrients* 2010, 2(11), 1141-1155
86. Andersson S, Ringström G, Elfvin A, Simrén M, Lönroth H, Abrahamsson H. Temporary percutaneous gastric electrical stimulation (GES). A novel technique tested in patients with non-established indications for GES. *Digestion.* 2011;83(1-2):3-12.
87. Borg J, Simrén M, Ohlsson B. Oxytocin reduces satiety scores without affecting the volume of nutrient intake or gastric emptying rate in healthy subjects *Neurogastroenterol Motil.* 2011 Jan;23(1):56-61.
88. Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in Irritable Bowel Syndrome – a randomized controlled trial. *Am J Gastroenterol* 2011 May;106(5):915-22.
89. Rao SS, Camilleri M, Hasler WL, Maurer AH, Parkman HP, Saad R, Scott MS, Simren M, Soffer E, Szarka L. Evaluation of gastrointestinal transit in clinical practice: position paper of the American and European Neurogastroenterology and Motility Societies. *Neurogastroenterol Motil.* 2011 Jan;23(1):8-23.
90. Krarup AL, Simrén M, Funch-Jensen P, Hansen MB, Hvid-Jensen F, Brun J, Drewes AM. The Esophageal Multimodal Pain Model: Normal Values and Degree of Sensitization in Healthy Young Male Volunteers. *Dig Dis Sci.* 2011 Jul;56(7):1967-75.

91. Ang D, Talley NJ, Simren M, Janssen P, Boeckxstaens G, Tack J. Review article: endpoints used in functional dyspepsia drug therapy trials. *Aliment Pharmacol Ther.* 2011 Mar;33(6):634-49.
92. Strid H, Simrén M, Störsrud S, Stotzer PO, Sadik R. Effect of heavy exercise on gastrointestinal transit in endurance athletes. *Scand J Gastroenterol.* 2011 Jun;46(6):673-7.
93. Krarup AL, Ny L, Astrand M, Bajor A, Hvid-Jensen F, Hansen MB, Simrén M, Funch-Jensen P, Drewes AM. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. *Aliment Pharmacol Ther.* 2011 May;33(10):1113-22.
94. Simrén M, Bajor A, Gillberg PG, Rudling M, Abrahamsson H. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation - a double-blind study. *Aliment Pharmacol Ther.* 2011 Jul;34(1):41-50.
95. Tack J, Müller-Lissner S, Stanghellini V, Boeckxstaens G, Kamm MA, Simren M, Galmiche JP, Fried M. Diagnosis and treatment of chronic constipation - a European perspective. *Neurogastroenterol Motil.* 2011 Aug;23(8):697-710
96. Asare F, Simrén M. Mindfulness-based stress reduction in patients with irritable bowel syndrome. *Aliment Pharmacol Ther.* 2011 Sep;34(5):578-9.
97. Zucchelli M, Camilleri M, Nixon Andreasson A, Bresso F, Dlugosz A, Halfvarson J, Törkvist L, Schmidt PT, Karling P, Ohlsson B, Duerr RH, Simren M, Lindberg G, Agreus L, Carlson P, Zinsmeister AR, D'Amato M. Association of TNFSF15 polymorphism with irritable bowel syndrome. *Gut.* 2011 Dec;60(12):1671-7
98. Pedersen SMM, Nebel C, Nielsen NC, Andersen HJ, Olsson J, Simrén M, Öhman L, Svensson U, Bertram HC, Malmendal A. A GC-MS-based Metabonomic Investigation of Blood Serum from Irritable Bowel Syndrome Patients Undergoing Intervention with Acidified Milk Products. *Eur Food Res Technol.* 2011;233:1013-1021.
99. Lindfors P, Unge P, Arvidsson P, Nyhlin H, Björnsson E, Abrahamsson H, Simrén M. Effects of gut-directed hypnotherapy on IBS in different clinical settings – results from two randomized, controlled trials. *Am J Gastroenterol* 2012 Feb;107(2):276-85
100. Engsbro AL, Simren M, Bytzer P. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification. *Aliment Pharmacol Ther.* 2012 Feb;35(3):350-9.
101. Öhman L, Stridsberg M, Isaksson S, Jerlstad P, Simrén M. Altered Levels of Fecal Chromogranins and Secretogranins in IBS: Relevance for Pathophysiology and Symptoms? *Am J Gastroenterol.* 2012 Mar;107(3):440-7
102. Öhman L, Lindmark AC, Isaksson S, Posserud I, Strid H, Sjövall H, Simrén M. Increased TLR2 expression on blood monocytes in irritable bowel syndrome patients. *Eur J Gastroenterol Hepatol.* 2012 Apr;24(4):398-405.

103. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. *Gut*. 2012 Jul;61(7):997-1006.
104. Törnblom H, Van Oudenhove L, Sadik R, Abrahamsson H, Tack J, Simrén M. Colonic Transit Time and IBS Symptoms: What's the Link? *Am J Gastroenterol*. 2012 May;107(5):754-60.
105. Asare F, Störsrud S, Simrén M. Meditation over medication for irritable bowel syndrome? On exercise and alternative treatments for irritable bowel syndrome. *Curr Gastroenterol Rep*. 2012 Aug;14(4):283-9.
106. Lindfors P, Unge P, Nyhlin H, Ljótsson B, Björnsson ES, Abrahamsson H, Simrén M. Long-term effects of hypnotherapy in patients with refractory irritable bowel syndrome. *Scand J Gastroenterol*. 2012 Apr;47(4):414-20.
107. Engsbro AL, Simrén M, Bytzer P. Commentary: short-term stability of subtypes in the irritable bowel syndromes - authors' reply. *Aliment Pharmacol Ther*. 2012 Apr;35(7):850-1.
108. Engsbro AL, Simrén M, Bytzer P. The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report. *Neurogastroenterol Motil*. 2012 Jul;24(7):604-11, e266.
109. Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA, Foxx-Orenstein AE, Guarner F, Gwee KA, Harris LA, Hungin AP, Hunt RH, Kellow JE, Khalif IL, Kruis W, Lindberg G, Olano C, Moraes-Filho JP, Schiller LR, Schmulson M, Simrén M, Tzortzon C. A global perspective on irritable bowel syndrome: a consensus statement of the world gastroenterology organisation summit task force on irritable bowel syndrome. *J Clin Gastroenterol*. 2012 May;46(5):356-66.
110. Keszthelyi D, Troost FJ, Simrén M, Ludidi S, Kruimel JW, Conchillo JM, Mascllee AA. Revisiting concepts of visceral nociception in irritable bowel syndrome. *Eur J Pain*. 2012 Nov;16(10):1444-54.
111. Farup PG, Sperber AD, Simrén M. Irritable Bowel Syndrome. *Gastroenterol Res Pract* 2012; 2012:612479.
112. Jeffery IB, Quigley EM, Ohman L, Simrén M, O'Toole PW. The microbiota link to Irritable Bowel Syndrome: An emerging story. *Gut Microbes*. 2012 Nov-Dec;3(6):572-6.
113. Böhn L, Störsrud S, Simrén M. Nutrient intake in patients with irritable bowel syndrome compared with the general population. *Neurogastroenterol Motil*. 2013 Jan;25(1):23-30.e1.
114. Ringström G, Störsrud S, Simrén M. A comparison of a short nurse-based and a long multidisciplinary version of structured patient education in irritable bowel syndrome. *Eur J Gastroenterol Hepatol*. 2012 Aug;24(8):950-7.
115. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. *Gut*. 2013 Jan;62(1):159-76.

116. Frøkjaer JB, Brock C, Brun J, Simren M, Dimcevski G, Funch-Jensen P, Drewes AM, Gregersen H. Esophageal distension parameters as potential biomarkers of impaired gastrointestinal function in diabetes patients. *Neurogastroenterol Motil.* 2012 Nov;24(11):1016-e544
117. Lindfors P, Ljótsson B, Björnsson E, Abrahamsson H, Simrén M. Patient satisfaction after gut-directed hypnotherapy in irritable bowel syndrome. *Neurogastroenterol Motil.* 2013 Feb;25(2):169-e86.
118. Lindfors P, Törnblom H, Sadik R, Björnsson E, Abrahamsson H, Simrén M. Effects on gastrointestinal transit and antroduodenal manometry after gut-directed hypnotherapy in Irritable Bowel Syndrome. *Scand J Gastroenterol.* 2012 Dec;47(12):1480-7
119. Frøkjær JB, Andersen LW, Brock C, Simrén M, Ljungberg M, Søfteland E, Dimcevski G, Yavarian Y, Gregersen H, Drewes AM. Altered Brain Microstructure Assessed by Diffusion Tensor Imaging in Patients With Diabetes Mellitus and Gastrointestinal Symptoms. *Diabetes Care.* 2013 Mar;36(3):662-8.
120. Labus J, Gupta A, Gill HK, Posserud I, Mayer M, Raeen H, Bolus R, Simren M, Naliboff BD, Mayer EA. Randomised clinical trial: symptoms of the irritable bowel syndrome are improved by a psycho-education group intervention. *Aliment Pharmacol Ther.* 2013 Feb;37(3):304-15.
121. Krarup AL, Ny L, Gunnarsson J, Hvid-Jensen F, Zetterstrand S, Simrén M, Funch-Jensen P, Hansen MB, Drewes AM. Randomized clinical trial: inhibition of the TRPV1 system in patients with nonerosive gastroesophageal reflux disease and a partial response to PPI treatment is not associated with analgesia to esophageal experimental pain. *Scand J Gastroenterol.* 2013 Mar;48(3):274-84.
122. Olausson EA, Brock C, Drewes AM, Grundin H, Isaksson M, Stotzer P, Abrahamsson H, Attvall S, Simrén M. Measurement of gastric emptying by radiopaque markers in patients with diabetes: correlation with scintigraphy and upper gastrointestinal symptoms. *Neurogastroenterol Motil.* 2013 Mar;25(3):e224-32.
123. Wallerstedt S, Simrén M, Wahlin S, Lööf L, Hultcrantz R, Sjöberg K, Gertzén HS, Prytz H, Almer S, Odén A. Moderate hyperkalemia in hospitalized patients with cirrhotic ascites indicates a poor prognosis. *Scand J Gastroenterol.* 2013 Mar;48(3):358-65.
124. Lasson A, Simrén M, Stotzer PO, Isaksson S, Ohman L, Strid H. Fecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. *Inflamm Bowel Dis.* 2013 Mar;19(3):576-81
125. Lelic D, Brock C, Søfteland E, Frøkjær JB, Andresen T, Simrén M, Drewes AM. Brain networks encoding rectal sensation in type 1 diabetes. *Neuroscience.* 2013 May 1;237:96-105.
126. Varkey J, Simrén M, Bosaeus I, Krantz M, Gäbel M, Herlenius G. Survival of patients evaluated for intestinal and multivisceral transplantation - the Scandinavian experience. *Scand J Gastroenterol.* 2013 Jun;48(6):702-11.

127. Ohman L, Simrén M. Intestinal microbiota and its role in irritable bowel syndrome (IBS). *Curr Gastroenterol Rep.* 2013 May;15(5):323.
128. Le Nevé B, Posserud I, Böhn L, Guyonnet D, Rondeau P, Tillisch K, Naliboff B, Mayer EA, Simrén M. A combined nutrient and lactulose challenge test allows symptom-based clustering of patients with irritable bowel syndrome. *Am J Gastroenterol.* 2013 May;108(5):786-95.
129. Böhn L, Störsrud S, Törnblom H, Bengtsson U, Simrén M. Self-reported food-related gastrointestinal symptoms in IBS are common and associated with more severe symptoms and reduced quality of life. *Am J Gastroenterol.* 2013 May;108(5):634-41.
130. Strid H, Simrén M, Lasson A, Isaksson S, Stridsberg M, Ohman L. Fecal chromogranins and secretogranins are increased in patients with ulcerative colitis but are not associated with disease activity. *J Crohns Colitis.* 2013 Dec 15;7(12):e615-22.
131. Farré R, Vanheel H, Vanuytsel T, Masaoka T, Törnblom H, Simrén M, Van Oudenhove L, Tack JF. In Functional Dyspepsia, Hypersensitivity to Postprandial Distention Correlates With Meal-Related Symptom Severity. *Gastroenterology.* 2013 Sep;145(3):566-73
132. Dahlén R, Strid H, Lundgren A, Isaksson S, Raghavan S, Magnusson MK, Simrén M, Sjövall H, Ohman L. Infliximab Inhibits Activation and Effector Functions of Peripheral Blood T cells in vitro from Patients with Clinically Active Ulcerative Colitis. *Scand J Immunol.* 2013 Sep;78(3):275-84
133. Jonefjäll B, Strid H, Ohman L, Svedlund J, Bergstedt A, Simren M. Characterization of IBS-like symptoms in patients with ulcerative colitis in clinical remission. *Neurogastroenterol Motil.* 2013 Sep;25(9):756-e578.
134. Frøkjær JB, Brock C, Søfteland E, Dimcevski G, Gregersen H, Simrén M, Drewes A. Macrostructural brain changes in patients with longstanding type 1 diabetes mellitus - a cortical thickness analysis study. *Exp Clin Endocrinol Diabetes.* 2013 Jun;121(6):354-60
135. Krarup AL, Gunnarsson J, Brun J, Poulakis A, Edebo A, Ringström G, Drewes AM, Simrén M. Exploration of the effects of gender and mild esophagitis on esophageal pain thresholds in the normal and sensitized state of asymptomatic young volunteers. *Neurogastroenterol Motil.* 2013 Sep;25(9):766-e580.
136. Ohman L, Dahlén R, Isaksson S, Sjöling A, Wick MJ, Sjövall H, Van Oudenhove L, Simrén M, Strid H. Serum IL-17A in Newly Diagnosed Treatment-Naïve Patients with Ulcerative Colitis Reflects Clinical Disease Severity and Predicts the Course of Disease. *Inflamm Bowel Dis.* 2013 Oct;19(11):2433-9.
137. Ringström G, Sjövall H, Simrén M, Jakobsson Ung E. The importance of a person-centered approach in diagnostic work-ups of patients with IBS: A qualitative study. *Gastroenterol Nurs.* 2013 Nov-Dec;36(6):443-51
138. Jakobsson-Ung E, Ringström G, Sjövall H, Simrén M. How patients with long-term experience of living with IBS manage illness in daily life –a qualitative study. *Eur J Gastroenterol Hepatol* 2013 Dec;25(12):1478-83

139. Lelic D, Brock C, Simrén M, Frøkjær JB, Søfteland E, Dimcevski G, Gregersen H, Drewes AM. The Brain Networks Encoding Visceral Sensation in Patients with Gastrointestinal Symptoms due to Diabetic Neuropathy. *Neurogastroenterol Motil* 2014 Jan;26(1):46-58.
140. Wouters MM, Lambrechts D, Knapp M, Cleynen I, Whorwell P, Agréus L, Dlugosz A, Schmidt PT, Halfvarsson J, Simrén M, Ohlsson B, Karling P, Van Wanrooy S, Mondelaers S, Vermeire S, Lindberg G, Spiller R, Dukes G, D'Amato M, Boeckxstaens G. Genetic variants in CDC42 and NXPH1 as susceptibility factors for constipation and diarrhea predominant irritable bowel syndrome. *Gut*. 2014 Jul;63(7):1103-11.
141. Brock C, Søfteland E, Gunterberg V, Frøkjær JB, Lelic D, Brock B, Dimcevski G, Gregersen H, Simrén M, Drewes AM. Diabetic Autonomic Neuropathy Affects Symptom Generation and Brain-Gut Axis. *Diabetes Care*. 2013 Nov;36(11):3698-705
142. Janssen P, Scott Harris M, Jones M, Masaoka T, Farré R, Törnblom H, Van Oudenhove L, Simrén M, Tack J. The relation between symptom improvement and gastric emptying in the treatment of diabetic and idiopathic gastroparesis. *Am J Gastroenterol*. 2013 Sep;108(9):1382-91.
143. Törnblom H, Van Oudenhove L, Tack J, Simrén M. Interaction between preprandial and postprandial rectal sensory and motor abnormalities in IBS. *Gut*. 2014 Sep;63(9):1441-9.
144. Björkman I, Dellenborg L, Ringström G, Simrén M, Jakobsson Ung E. The gendered impact of Irritable Bowel Syndrome: a qualitative study of patients' experiences. *J Adv Nurs*. 2014 Jun;70(6):1334-43.
145. Simrén M. Diet as a therapy for irritable bowel syndrome: progress at last. *Gastroenterology*. 2014 Jan;146(1):10-2
146. Søfteland E, Brock C, Frøkjær JB, Brøgger J, Madácsy L, Gilja OH, Arendt-Nielsen L, Simrén M, Drewes AM, Dimcevski G. Association between visceral, cardiac and sensorimotor polyneuropathies in diabetes mellitus. *J Diabetes Complications*. 2014 May-Jun;28(3):370-7
147. Olausson EA, Störsrud S, Grundin H, Isaksson M, Attvall S, Simrén M. A Small Particle Size Diet Reduces Upper Gastrointestinal Symptoms in Patients With Diabetic Gastroparesis: A Randomized Controlled Trial. *Am J Gastroenterol*. 2014 Mar;109(3):375-85.
148. Simrén M. IBS with intestinal microbial dysbiosis: a new and clinically relevant subgroup? *Gut*. 2014 Nov;63(11):1685-6
149. Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. *Gut*. 2015 Jan;64(1):84-92
150. Uusijärvi A, Bergström A, Simrén M, Ludvigsson JF, Kull I, Wickman M, Alm J, Olén O. Use of antibiotics in infancy and childhood and risk of recurrent abdominal pain--a Swedish birth cohort study. *Neurogastroenterol Motil*. 2014 Jun;26(6):841-50.
151. Bashashati M, Rezaei N, Shafeyoun A, McKernan DP, Chang L, Ohman L, Quigley EM, Schmulson M, Sharkey KA, Simrén M. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. *Neurogastroenterol Motil*. 2014 Jul;26(7):1036-48.

152. Olausson EA, Grundin H, Isaksson M, Brock C, Drewes AM, Attvall S, Simrén M. Postprandial Plasma Glucose Response and Gastrointestinal Symptom Severity in Patients With Diabetic Gastroparesis. *J Diabetes Sci Technol.* 2014 Jul;8(4):881-8.
153. Doré J, Simrén M, Buttle L, Guarner F. Hot topics in gut microbiota. *United European Gastroenterol J.* 2013 Oct;1(5):311-8.
154. Posserud I, Strid H, Störsrud S, Törnblom H, Svensson U, Tack J, Van Oudenhove L, Simrén M. Symptom pattern following a meal challenge test in patients with irritable bowel syndrome and healthy controls. *United European Gastroenterol J.* 2013 Oct;1(5):358-67.
155. Emmanuel A, Quigley EM, Simrén M, Feng Y, Müller-Lissner S, Urbain D, Tack J, Bredenoord AJ, Sabaté JM, Yiannakou Y, Andresen V, Cuomo R, Rey E, Gryp RS, Vandeplassche L, Solomon D. Factors affecting satisfaction with treatment in European women with chronic constipation: An internet survey. *United European Gastroenterol J.* 2013 Oct;1(5):375-84.
156. Magnusson MK, Dahlén R, Strid H, Isaksson S, Simrén M, Lasson A, Bajor A, Ung KA, Ohman L. CD25 and TNF receptor II reflect early primary response to infliximab therapy in patients with ulcerative colitis. *United European Gastroenterol J.* 2013 Dec;1(6):467-76.
157. Nielsen LM, Olesen AE, Andresen T, Simrén M, Törnblom H, Drewes AM. Efficacy and Safety of PPC-5650 on Experimental Rectal Pain in Patients with Irritable Bowel Syndrome. *Basic Clin Pharmacol Toxicol.* 2015 Feb;116(2):140-5.
158. Bajor A, Törnblom H, Rudling M, Ung KA, Simrén M. Authors' response: Bile acids are important in the pathophysiology of IBS. *Gut.* 2015 May;64(5):851-2.
159. Søfteland E, Brock C, Frøkjær JB, Simrén M, Drewes AM, Dimcevski G. Rectal sensitivity in diabetes patients with symptoms of gastroparesis. *J Diabetes Res.* 2014;2014:784841.
160. Krarup AL, Peterson E, Ringström G, Törnblom H, Hjortswang H, Simrén M. The Short Health Scale: A Simple, Valid, Reliable, and Responsive Way of Measuring Subjective Health in Patients With Irritable Bowel Syndrome. *J Clin Gastroenterol.* 2015 Aug;49(7):565-70
161. Ek WE, Reznichenko A, Ripke S, Niesler B, Zucchelli M, Rivera NV, Schmidt PT, Pedersen NL, Magnusson P, Talley NJ, Holliday EG, Houghton L, Gazouli M, Karamanolis G, Rappold G, Burwinkel B, Surowy H, Rafter J, Assadi G, Li L, Papadaki E, Gambaccini D, Marchi S, Colucci R, Blandizzi C, Barbaro R, Karling P, Walter S, Ohlsson B, Tornblom H, Bresso F, Andreasson A, Dlugosz A, Simren M, Agreus L, Lindberg G, Boeckxstaens G, Bellini M, Stanghellini V, Barbara G, Daly MJ, Camilleri M, Wouters MM, D'Amato M. Exploring the genetics of irritable bowel syndrome: a GWA study in the general population and replication in multinational case-control cohorts. *Gut.* 2015 Nov;64(11):1774-82.
162. Olén O, Neuman A, Koopmann B, Ludvigsson JF, Ballardini N, Westman M, Melén E, Kull I, Simrén M, Bergström A. Allergy-related diseases and recurrent abdominal pain during childhood - a birth cohort study. *Aliment Pharmacol Ther.* 2014 Dec;40(11-12):1349-58.

163. Ohman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. *Nat Rev Gastroenterol Hepatol*. 2015 Jan;12(1):36-49.
164. Varkey J, Simrén M, Jalanko H, Oltean M, Saalman R, Gudjonsdottir A, Gäbel M, Borg H, Edenholm M, Bentdal O, Husby S, Staun M, Mäkipalo H, Bosaeus I, Olausson M, Pakarinen M, Herlenius G. Fifteen years' experience of intestinal and multivisceral transplantation in the Nordic countries. *Scand J Gastroenterol*. 2015 Mar;50(3):278-90.
165. Törnblom H, Simrén M, Abrahamsson H. Gastrointestinal motility and neurogastroenterology. *Scand J Gastroenterol*. 2015 Jun;50(6):685-97.
166. Piessevaux H, Corazziari E, Rey E, Simren M, Wiechowska-Kozlowska A, Kerstens R, Cools M, Barrett K, Levine A. A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of long-term treatment with prucalopride. *Neurogastroenterol Motil*. 2015 Jun;27(6):805-15
167. Björkman I, Jakobsson Ung E, Ringström G, Törnblom H, Simrén M. More similarities than differences between men and women with irritable bowel syndrome. *Neurogastroenterol Motil*. 2015 Jun;27(6):796-804
168. Drewes AM, Munkholm P, Simrén M, Breivik H, Kongsgaard UE, Hatlebakk J, Agréus L, Friedrichsen L, Christrup LL. Definition, diagnosis and treatment strategies for opioid-induced bowel dysfunction-Recommendations of the Nordic Working Group. *Scand J Pain*. 2016;11:11-122
169. Bennet SM, Ohman L, Simren M. Gut microbiota as potential orchestrators of irritable bowel syndrome. *Gut Liver*. 2015 May 23;9(3):318-31
170. Casén C, Vebø HC, Sekelja M, Hegge FT, Karlsson MK, Ciemniejewska E, Dzankovic S, Frøyland C, Nestestog R, Engstrand L, Munkholm P, Nielsen OH, Rogler G, Simrén M, Öhman L, Vatn MH, Rudi K. Deviations in human gut microbiota: a novel diagnostic test for determining dysbiosis in patients with IBS or IBD. *Aliment Pharmacol Ther*. 2015 Jul;42(1):71-83.
171. Lövdahl J, Ringström G, Agerforz P, Törnblom H, Simrén M. Nurse-Administered, Gut-Directed Hypnotherapy in IBS: Efficacy and Factors Predicting a Positive Response. *Am J Clin Hypn*. 2015;58(1):100-14.
172. Jonefjäll B, Simrén M, Öhman L, Lasson A, Svedlund J, Strid H. The severity of inflammation at onset of ulcerative colitis is not associated with IBS-like symptoms during clinical remission. *J Crohns Colitis*. 2015 Sep;9(9):776-83.
173. Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Simrén M. Diet low in FODMAPs Reduces Symptoms of Irritable Bowel Syndrome as Well as Traditional Dietary Advice: A Randomized Controlled Trial. *Gastroenterology*. 2015 Nov;149(6):1399-1407.e2.
174. Stotzer PO, Abrahamsson H, Bajor A, Kilander A, Sadik R, Sjövall H, Simrén M. Are the definitions for chronic diarrhoea adequate? Evaluation of two different definitions in patients with chronic diarrhoea. *United European Gastroenterol J*. 2015 Aug;3(4):381-6

175. Störsrud S, Pontén I, Simrén M. A Pilot Study of the Effect of Aloe barbadensis Mill. Extract (AVH200®) in Patients with Irritable Bowel Syndrome: a Randomized, Double-Blind, Placebo-Controlled Study. *J Gastrointest Liver Dis.* 2015 Sep;24(3):275-80.
176. Grinsvall C, Törnblom H, Tack J, Van Oudenhove L, Simrén M. Psychological factors selectively upregulate rectal pain perception in hypersensitive patients with irritable bowel syndrome. *Neurogastroenterol Motil.* 2015 Dec;27(12):1772-82.
177. Törnblom H, Simrén M. In search for a disease-modifying treatment in irritable bowel syndrome. *Gut.* 2016 Jan;65(1):2-3.
178. Le Nevé B, Brazeilles R, Derrien M, Tap J, Guyonnet D, Ohman L, Törnblom H, Simrén M. Lactulose Challenge Determines Visceral Sensitivity and Severity of Symptoms in Patients With Irritable Bowel Syndrome. *Clin Gastroenterol Hepatol.* 2016 Feb;14(2):226-233.e3
179. Almquist E, Törnblom H, Simrén M. Practical management of irritable bowel syndrome: a clinical review. *Minerva Gastroenterol Dietol.* 2016 Mar;62(1):30-48
180. Van Oudenhove L, Törnblom H, Störsrud S, Tack J, Simrén M. Depression and somatization are associated with increased postprandial symptoms in patients with irritable bowel syndrome. *Gastroenterology* 2016 Apr;150(4):866-74.
181. Simrén M, Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H. Reply. *Gastroenterology.* 2016 Apr;150(4):1047-8.
182. Le Neve B, Brazeilles R, Derrien M, Tap J, Guyonnet D, Ohman L, Törnblom H, Simren M. Reply. *Clin Gastroenterol Hepatol.* 2016 Feb;14(2):226-33.e1-3.
183. Mottacki N, Simrén M, Bajor A. Review article: bile acid diarrhoea - pathogenesis, diagnosis and management. *Aliment Pharmacol Ther.* 2016 Apr;43(8):884-898
184. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. *Gastroenterology.* 2016; 150:1393-1407
185. Keefer L, Drossman DA, Guthrie E, Simrén M, Tillisch K, Olden K, Whorwell PJ. Centrally Mediated Disorders of Gastrointestinal Pain. *Gastroenterology.* 2016;150:1408-1419
186. Enck P, Aziz Q, Barbara G, Farmer AD, Fukudo S, Mayer EA, Niesler B, Quigley EM, Rajilić-Stojanović M, Schemann M, Schwille-Kiuntke J, Simren M, Zipfel S, Spiller RC. Irritable bowel syndrome. *Nat Rev Dis Primers.* 2016 Mar 24;2:16014.
187. Whitehead WE, Palsson OS, Simren M. Treating Fecal Incontinence: An Unmet Need in Primary Care Medicine. *N C Med J.* 2016 May-Jun;77(3):211-5.
188. Whitehead WE, Palsson OS, Simrén M. Biomarkers to distinguish functional constipation from irritable bowel syndrome with constipation. *Neurogastroenterol Motil.* 2016 Jun;28(6):783-92.
189. Björkman I, Simrén M, Ringström G, Jakobsson Ung E. Patients' experiences of health care encounters in severe irritable bowel syndrome: an analysis based on narrative and feminist theory. *J Clin Nurs.* 2016 Oct;25(19-20):2967-78
190. Gunterberg V, Simrén M, Öhman L, Friberg P, Jones MP, Van Oudenhove L, Strid H. Autonomic nervous system function predicts the inflammatory response over three years in

- newly diagnosed ulcerative colitis patients. *Neurogastroenterol Motil.* 2016 Nov;28(11):1655-1662
191. Boeckxstaens GE, Drug V, Dumitrescu D, Farmer AD, Hammer J, Hausken T, Niesler B, Pohl D, Pojskic L, Polster A, Simren M, Goebel-Stengel M, Van Oudenhove L, Vassallo M, Wensaas KA, Aziz Q, Houghton LA; COST Action BM1106 GENIEUR members. Phenotyping of subjects for large scale studies on patients with IBS. *Neurogastroenterol Motil.* 2016 Aug;28(8):1134-47
192. Bennet SM, Polster A, Törnblom H, Isaksson S, Capronnier S, Tessier A, Le Nevé B, Simrén M, Öhman L. Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome. *Am J Gastroenterol.* 2016 Aug;111(8):1165-76
193. Frändemark Å, Jakobsson Ung E, Törnblom H, Simrén M, Jakobsson S. Fatigue: a distressing symptom for patients with irritable bowel syndrome. *Neurogastroenterol Motil.* 2017 Jan;29(1):e12898
194. Simrén M, Palsson O, Heymen S, Bajor A, Törnblom H, Whitehead WE. Fecal incontinence in irritable bowel syndrome: Prevalence and associated factors in Swedish and American patients. *Neurogastroenterol Motil.* 2017 Feb;29(2):e12919.
195. Tap J, Derrien M, Törnblom H, Brazeilles R, Cools-Portier S, Doré J, Störsrud S, Le Nevé B, Öhman L, Simrén M. Identification of an Intestinal Microbiota Signature Associated With Severity of Irritable Bowel Syndrome. *Gastroenterology.* 2017 Jan;152(1):111-123.e8.
196. Jonefjäll B, Öhman L, Simrén M, Strid H. IBS-like Symptoms in Patients with Ulcerative Colitis in Deep Remission Are Associated with Increased Levels of Serum Cytokines and Poor Psychological Well-being. *Inflamm Bowel Dis.* 2016 Nov;22(11):2630-2640.
197. Bonnert M, Olén O, Lalouni M, Benninga MA, Bottai M, Engelbrektsson J, Hedman E, Lenhard F, Melin B, Simrén M, Vigerland S, Serlachius E, Ljótsson B. Internet-Delivered Cognitive Behavior Therapy for Adolescents With Irritable Bowel Syndrome: A Randomized Controlled Trial. *Am J Gastroenterol.* 2017 Jan;112(1):152-162.
198. Henström M, Diekmann L, Bonfiglio F, Hadizadeh F, Kuech EM, von Köckritz-Blickwede M, Thingholm LB, Zheng T, Assadi G, Dierks C, Heine M, Philipp U, Distl O, Money ME, Belheouane M, Heinsen FA, Rafter J, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Walter S, Simrén M, Karling P, Ohlsson B, Schmidt PT, Lindberg G, Dlugosz A, Agreus L, Andreasson A, Mayer E, Baines JF, Engstrand L, Portincasa P, Bellini M, Stanghellini V, Barbara G, Chang L, Camilleri M, Franke A, Naim HY, D'Amato M. Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome. *Gut.* 2018 Feb;67(2):263-270.
199. Frøkjær JB, Graversen C, Brock C, Khodayari-Rostamabad A, Olesen SS, Hansen TM, Søfteland E, Simrén M, Drewes AM. Integrity of central nervous function in diabetes mellitus assessed by resting state EEG frequency analysis and source localization. *J Diabetes Complications.* 2017 Feb;31(2):400-406.

200. Tack J, Boardman H, Layer P, Schiefke I, Jayne D, Scarpignato C, Fox M, Frieling T, Ducrotte P, Hamdy S, Gill K, Ciriza de Los Rios C, Felt-Bersma R, De Looze D, Stanghellini V, Drewes AM, Simrén M, Pehl C, Hoheisel T, Leodolter A, Rey E, Dalrymple J, Emmanuel A. An expert consensus definition of failure of a treatment to provide adequate relief (F-PAR) for chronic constipation - an international Delphi survey. *Aliment Pharmacol Ther.* 2017 Feb;45(3):434-442.
201. Aroniadis OC, Drossman DA, Simren M. A Perspective on Brain-Gut Communication: The American Gastroenterology Association and American Psychosomatic Society Joint Symposium on Brain-gut Interactions and the Intestinal Microenvironment. *Psychosom Med.* 2017 Oct;79(8):847-856
202. Lebrero-Fernández C, Wenzel UA, Akeus P, Wang Y, Strid H, Simrén M, Gustavsson B, Börjesson LG, Cardell SL, Öhman L, Quiding-Järbrink M, Bas-Forsberg A. Altered expression of Butyrophilin (*BTN*) and *BTN*-like (*BTNL*) genes in intestinal inflammation and colon cancer. *Immun Inflamm Dis.* 2016 Apr 1;4(2):191-200.
203. Vanheel H, Carbone F, Valvekens L, Simren M, Tornblom H, Vanuytsel T, Van Oudenhove L, Tack J. Pathophysiological Abnormalities in Functional Dyspepsia Subgroups According to the Rome III Criteria. *Am J Gastroenterol.* 2017 Jan;112(1):132-140.
204. Henström M, Hadizadeh F, Beyder A, Bonfiglio F, Zheng T, Assadi G, Rafter J, Bujanda L, Agreus L, Andreasson A, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Talley NJ, Simren M, Walter S, Wouters M, Farrugia G, D'Amato M. TRPM8 polymorphisms associated with increased risk of IBS-C and IBS-M. *Gut.* 2017 Sep;66(9):1725-1727.
205. Varkey J, Oltean M, Pischel AB, Simrén M, Herlenius G. Initial Experience of Video Capsule Endoscopy After Intestinal Transplantation. *Transplant Direct.* 2016 Nov 18;2(12):e119.
206. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P, Satokari R, Sokol H, Arkkila P, Pintus C, Hart A, Segal J, Aloia M, Masucci L, Molinaro A, Scaldaferri F, Gasbarrini G, Lopez-Sanroman A, Link A, de Groot P, de Vos WM, Högenauer C, Malfertheiner P, Mattila E, Milosavljević T, Nieuwdorp M, Sanguinetti M, Simren M, Gasbarrini A; European FMT Working Group. European consensus conference on faecal microbiota transplantation in clinical practice. *Gut.* 2017 Apr;66(4):569-580.
207. Simrén M, Törnblom H, Palsson OS, Whitehead WE. Management of the multiple symptoms of irritable bowel syndrome. *Lancet Gastroenterol Hepatol.* 2017 Feb;2(2):112-122
208. Aziz I, Törnblom H, Simrén M. Small intestinal bacterial overgrowth as a cause for irritable bowel syndrome: guilty or not guilty? *Curr Opin Gastroenterol.* 2017 May;33(3):196-202.
209. Whitehead WE, Palsson OS, Simrén M. Irritable bowel syndrome: what do the new Rome IV diagnostic guidelines mean for patient management? *Expert Review of Gastroenterology and Hepatology* 2017 Apr;11(4):281-283.
210. Simrén M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. *Curr Gastroenterol Rep* 2017 Apr;19(4):15.

211. Heymen S, Palsson O, Simrén M, Whitehead WE. Patient preferences for endpoints in fecal incontinence treatment studies. *Neurogastroenterol Motil* 2017 [Epub ahead of print]
212. Agreus L, Simrén M. Nya riktlinjer för handläggning av dyspepsi, H pylori och magsår. *Lakartidningen*. 2017 Feb 28;114.
213. Wilpart K, Törnblom H, Svedlund J, Tack JF, Simrén M, Van Oudenhove L. Coping Skills are Associated With Gastrointestinal Symptom Severity and Somatization in Patients With Irritable Bowel Syndrome. *Clin Gastroenterol Hepatol*. 2017 Oct;15(10):1565-1571.e3.
214. Ianiro G, Simren M. How to get your work published: Tricks and pearls. *United European Gastroenterol J*. 2017 Mar;5(2):300-301.
215. Sundin J, Öhman L, Simren M. Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. *Psychosom Med*. 2017 Oct;79(8):857-867.
216. Magnusson MK, Strid H, Isaksson S, Simrén M, Öhman L. The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis. *Inflamm Bowel Dis*. 2017 Jun;23(6):956-966.
217. Appleby RN, Bajor A, Gillberg PG, Graffner H, Simrén M, Ung KA, Walters J. Effects of conventional and a novel colonic-release bile acid sequestrant, A3384, on fibroblast growth factor 19 and bile acid metabolism in healthy volunteers and patients with bile acid diarrhoea. *United European Gastroenterol J*. 2017 Apr;5(3):380-388
218. Polster A, Van Oudenhove L, Jones M, Öhman L, Törnblom H, Simrén M. Mixture model analysis identifies irritable bowel syndrome subgroups characterised by specific profiles of gastrointestinal, extraintestinal somatic and psychological symptoms. *Aliment Pharmacol Ther*. 2017 Sep;46(5):529-539
219. Tack J, Corsetti M, Camilleri M, Quigley EM, Simren M, Suzuki H, Talley NJ, Tornblom H, Van Oudenhove L. Plausibility criteria for putative pathophysiological mechanisms in functional gastrointestinal disorders: a consensus of experts. *Gut*. 2018 Aug;67(8):1425-1433.
220. Bashashati M, Moossavi S, Cremon C, Barbaro MR, Moraveji S, Talmon G, Rezaei N, Hughes PA, Bian ZX, Choi CH, Lee OY, Coëffier M, Chang L, Ohman L, Schmulson MJ, McCallum RW, Simren M, Sharkey KA, Barbara G. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis. *Neurogastroenterol Motil*. 2018 Jan;30(1). doi: 10.1111/nmo.13192
221. Polster A, Van Oudenhove L, Jones M, Öhman L, Törnblom H, Simrén M. Editorial: subgroups in irritable bowel syndrome-more than just diarrhoea and constipation? Authors' reply. *Aliment Pharmacol Ther*. 2017 Oct;46(7):698-699.
222. Wohlfarth C, Schmitteckert S, Härtle JD, Houghton LA, Dweeb H, Fortea M, Assadi G, Braun A, Mederer T, Pöhner S, Becker PP, Fischer C, Granzow M, Mönnikes H, Mayer EA, Sayuk G, Boeckxstaens G, Wouters MM, Simrén M, Lindberg G, Ohlsson B, Schmidt PT, Dlugosz A, Agreus L, Andreasson A, D'Amato M, Burwinkel B, Bermejo JL, Röth R, Lasitschka F,

- Vicario M, Metzger M, Santos J, Rappold GA, Martinez C, Niesler B. miR-16 and miR-103 impact 5-HT4 receptor signalling and correlate with symptom profile in irritable bowel syndrome. *Sci Rep.* 2017 Oct 31;7(1):14680.
223. Vork L, Keszthelyi D, Mujagic Z, Kruimel JW, Leue C, Pontén I, Törnblom H, Simrén M, Albu-Soda A, Aziz Q, Corsetti M, Holvoet L, Tack J, Rao SS, van Os J, Quetglas EG, Drossman DA, Masclee AAM. Development, content validity, and cross-cultural adaptation of a patient-reported outcome measure for real-time symptom assessment in irritable bowel syndrome. *Neurogastroenterol Motil.* 2018 Mar;30(3). doi: 10.1111/nmo.13244.
224. Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. The Prevalence and Impact of Overlapping Rome IV-Diagnosed Functional Gastrointestinal Disorders on Somatization, Quality of Life, and Healthcare Utilization: A Cross-Sectional General Population Study in Three Countries. *Am J Gastroenterol.* 2018 Jan;113(1):86-96
225. Paterson W, Camilleri M, Simren M, Boeckxstaens G, Vanner SJ. Breath Testing Consensus Guidelines for SIBO: RES IPSA LOCQUITOR. *Am J Gastroenterol.* 2017 Dec;112(12):1888-1889
226. Lundgren-Nilsson Å, Tennant A, Jakobsson S, Simrén M, Taft C, Dencker A. Validation of Fatigue Impact Scale with various item sets - a Rasch analysis. *Disabil Rehabil.* 2019 Apr;41(7):840-846.
227. Varkey J, Stotzer PO, Simrén M, Herlenius G, Oltean M. The endoscopic surveillance of the transplanted small intestine: a single center experience and a proposal for a grading score. *Scand J Gastroenterol.* 2018 Feb;53(2):134-139
228. Camilleri M, Ford AC, Mawe GM, Dinning PG, Rao SS, Chey WD, Simrén M, Lembo A, Young-Fadok TM, Chang L. Chronic constipation. *Nat Rev Dis Primers.* 2017 Dec 14;3:17095. doi: 10.1038/nrdp.2017.95.
229. Aziz I, Palsson OS, Törnblom H, Sperber AD, Whitehead WE, Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. *Lancet Gastroenterol Hepatol.* 2018 Apr;3(4):252-262.
230. Simrén M, Törnblom H, Palsson OS, van Tilburg MA, Van Oudenhove L, Tack J, Whitehead WE. Visceral hypersensitivity is associated with GI symptom severity in functional GI disorders: consistent findings from five different patient cohorts. *Gut.* 2018 Feb;67(2):255-262.
231. Garcia-Etxebarria K, Zheng T, Bonfiglio F, Bujanda L, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Simren M, Walter S, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Jonkers D, Eswaran S, Chey WD, Kashyap P, Chang L, Mayer EA, Wouters MM, Boeckxstaens G, Camilleri M, Franke A, D'Amato M. Increased prevalence of rare sucrase-isomaltase (SI) pathogenic variants in irritable bowel syndrome patients. *Clin Gastroenterol Hepatol.* 2018 Oct;16(10):1673-1676.

232. Jonefjäll B, Simrén M, Lasson A, Öhman L, Strid H. Psychological distress, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with ulcerative colitis. *United European Gastroenterol J.* 2018 Feb;6(1):148-158.
233. Bennet SMP, Böhn L, Störsrud S, Liljebo T, Collin L, Lindfors P, Törnblom H, Öhman L, Simrén M. Multivariate modelling of faecal bacterial profiles of patients with IBS predicts responsiveness to a diet low in FODMAPs. *Gut.* 2018 May;67(5):872-881
234. Clevers E, Tack J, Törnblom H, Ringström G, Luyckx K, Simrén M, Van Oudenhove L. Development of Irritable Bowel Syndrome Features Over a 5-year Period. *Clin Gastroenterol Hepatol.* 2018 Aug;16(8):1244-1251.e1.
235. Clevers E, Whitehead WE, Palsson OS, Sperber AD, Törnblom H, Van Oudenhove L, Tack J, Simrén M. Factor Analysis Defines Distinct Upper and Lower Gastrointestinal Symptom Groups Compatible With Rome IV Criteria in a Population-based Study. *Clin Gastroenterol Hepatol.* 2018 Aug;16(8):1252-1259.e5
236. Grinsvall C, Törnblom H, Tack J, Van Oudenhove L, Simrén M. Relationships between psychological state, abuse, somatization and visceral pain sensitivity in irritable bowel syndrome. *United European Gastroenterol J.* 2018 Mar;6(2):300-309.
237. Lagerlöf E, Agreus L, Simrén M, Törnblom H. ABC om - IBS – irritabel tarm. *Lakartidningen.* 2018 Mar 7;115.
238. Clevers E, Vaes B, Henrard S, Goderis G, Tack J, Törnblom H, Simrén M, Van Oudenhove L. Health problems associated with irritable bowel syndrome: analysis of a primary care registry. *Aliment Pharmacol Ther.* 2018 May;47(10):1349-1357.
239. Polster A, Friberg P, Gunterberg V, Öhman L, Le Nevé B, Törnblom H, Cvijovic M, Simren M. Heart rate variability characteristics of patients with irritable bowel syndrome and associations with symptoms. *Neurogastroenterol Motil.* 2018 Jul;30(7):e13320.
240. Keller J, Bassotti G, Clarke J, Dinning P, Fox M, Grover M, Hellström PM, Ke M, Layer P, Malagelada C, Parkman HP, Scott SM, Tack J, Simren M, Törnblom H, Camilleri M; International Working Group for Disorders of Gastrointestinal Motility and Function. Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders. *Nat Rev Gastroenterol Hepatol.* 2018 May;15(5):291-308.
241. Bonfiglio F, Zheng T, Garcia-Etxebarria K, Hadizadeh F, Bujanda L, Bresso F, Agreus L, Andreasson A, Dlugosz A, Lindberg G, Schmidt PT, Karling P, Ohlsson B, Simren M, Walter S, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Latiano A, Hüenthal M, Thijs V, Netea MG, Jonkers D, Chang L, Mayer EA, Wouters MM, Boeckxstaens G, Camilleri M, Franke A, Zhernakova A, D'Amato M. Female-specific Association Between Variants on Chromosome 9 and Self-reported Diagnosis of Irritable Bowel Syndrome. *Gastroenterology.* 2018 Jul;155(1):168-179.
242. Pohl D, Van Oudenhove L, Törnblom H, Le Nevé B, Tack J, Simrén M. Functional Dyspepsia and Severity of Psychologic Symptoms Associate With Postprandial Symptoms

- in Patients With Irritable Bowel Syndrome. *Clin Gastroenterol Hepatol.* 2018 Nov;16(11):1745-1753.e1
243. Bennet SMP, Palsson O, Whitehead WE, Barrow DA, Törnblom H, Öhman L, Simrén M, van Tilburg MAL. Systemic cytokines are elevated in a subset of patients with irritable bowel syndrome but largely unrelated to symptom characteristics. *Neurogastroenterol Motil.* 2018 Oct;30(10):e13378
244. Nybacka S, Öhman L, Störsrud S, Mybeck M, Böhn L, Wilpart K, Winkvist A, Bengtsson U, Törnblom H, Simrén M. Neither self-reported atopy nor IgE-mediated allergy are linked to gastrointestinal symptoms in patients with irritable bowel syndrome. *Neurogastroenterol Motil.* 2018 Oct;30(10):e13379
245. Aziz I, Palsson OS, Whitehead WE, Sperber AD, Simrén M, Törnblom H. Epidemiology, Clinical Characteristics, and Associations for Rome IV Functional Nausea and Vomiting Disorders in Adults. *Clin Gastroenterol Hepatol.* 2019 Apr;17(5):878-886.
246. Aziz I, Törnblom H, Palsson OS, Whitehead WE, Simrén M. How the Change in IBS Criteria From Rome III to Rome IV Impacts on Clinical Characteristics and Key Pathophysiological Factors. *Am J Gastroenterol.* 2018 Jul;113(7):1017-1025.
247. Simrén M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. *Nat Rev Gastroenterol Hepatol.* 2018 Oct;15(10):589-605.
248. Olén O, Stephansson O, Backman AS, Törnblom H, Simrén M, Altman M. Pre- and perinatal stress and irritable bowel syndrome in young adults - A nationwide register-based cohort study. *Neurogastroenterol Motil.* 2018 Nov;30(11):e13436.
249. Törnblom H, Simrén M, Barbara G, Niesler B. Funding for gastrointestinal disease research in the European Union. *Lancet Gastroenterol Hepatol.* 2018 Sep;3(9):593-595.
250. Simrén M. Manipulating the gut microbiome as a treatment strategy for functional gastrointestinal disorders. *Gastroenterology.* 2018 Oct;155(4):960-962.
251. Bennet SMP, Sundin J, Magnusson MK, Strid H, Tap J, Derrien M, Le Nevé B, Doré J, Törnblom H, Simrén M, Öhman L. Altered intestinal antibacterial gene expression response profile in irritable bowel syndrome is linked to bacterial composition and immune activation. *Neurogastroenterol Motil.* 2018 Dec;30(12):e13468
252. Josefsson A, Palsson O, Simrén M, Sperber AD, Törnblom H, Whitehead W. Oesophageal symptoms are common and associated with other functional gastrointestinal disorders (FGIDs) in an English-speaking Western population. *UEG Journal* 2018 Dec;6(10):1461-1469.
253. Frändemark Å, Törnblom H, Jakobsson S, Simrén M. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. *Am J Gastroenterol.* 2018 Oct;113(10):1540-1549.
254. Shulman RJ, Öhman L, Stridsberg M, Cain K, Simrén M, Heitkemper M. Evidence of increased fecal granins in children with irritable bowel syndrome and correlates with symptoms. *Neurogastroenterol Motil.* 2018 Jan;31(1):e13486.

255. Clevers E, Whitehead WE, Palsson OS, Sperber AD, Törnblom H, Van Oudenhove L, Tack J, Simrén M. Reply. *Clin Gastroenterol Hepatol*. 2019 Apr;17(5):1002-1004.
256. Polster AV, Palsson OS, Törnblom H, Öhman L, Sperber AD, Whitehead WE, Simrén M. Subgroups of IBS patients are characterized by specific, reproducible profiles of GI and non-GI symptoms and report differences in healthcare utilization: A population-based study. *Neurogastroenterol Motil*. 2019 Jan;31(1):e13483.
257. Smeets FGM, Keszhelyi D, Vork L, Tack J, Talley NJ, Simren M, Aziz Q, Ford AC, Conchillo JM, Kruimel JW, Van Os J, Mascllee AAM. Development of a real-time patient-reported outcome measure for symptom assessment in patients with functional dyspepsia using the experience sampling method. *Neurogastroenterol Motil*. 2019 Feb;31(2):e13496.
258. Sundin J, Stridsberg M, Tap J, Derrien M, Le Nevé B, Doré J, Törnblom H, Simrén M, Öhman L. Fecal chromogranins and secretogranins are linked to the fecal and mucosal intestinal bacterial composition of IBS patients and healthy subjects. *Sci Rep*. 2018 Nov 14;8(1):16821.
259. Lalouni M, Ljótsson B, Bonnert M, Ssegona R, Benninga M, Bjureberg J, Höglström J, Sahlin H, Simrén M, Feldman I, Hedman-Lagerlöf E, Serlachius E, Olén O. Clinical and Cost Effectiveness of Online Cognitive Behavioral Therapy in Children with Functional Abdominal Pain Disorders. *Clin Gastroenterol Hepatol*. 2019 Oct;17(11):2236-2244.e11.
260. Tap J, Cools-Portier S, Pavan S, Druesne A, Öhman L, Törnblom H, Simren M, Derrien M. Effects of the long-term storage of human fecal microbiota samples collected in RNAlater. *Sci Rep*. 2019 Jan 24;9(1):601.
261. Jakobsson S, Eliasson B, Andersson E, Johannsson G, Ringström G, Simrén M, Jakobsson Ung E. Person-centred inpatient care - A quasi-experimental study in an internal medicine context. *J Adv Nurs*. 2019 Aug;75(8):1678-1689.
262. Mavroudis G, Simren M, Jonefjäll B, Öhman L, Strid H. Symptoms compatible with functional bowel disorders are common in patients with quiescent ulcerative colitis and influence the quality of life but not the course of the disease. *Therap Adv Gastroenterol*. 2019 Feb 19;12:1756284819827689. doi: 10.1177/1756284819827689. eCollection 2019.
263. Nybacka S, Störsrud S, Liljebo T, Le Nevé B, Törnblom H, Simrén M, Winkvist A. Within- and Between-Subject Variation in Dietary Intake of Fermentable Oligo-, Di-, Monosaccharides, and Polyols Among Patients with Irritable Bowel Syndrome. *Curr Dev Nutr*. 2018 Dec 24;3(2):nzy101.
264. Labus JS, Osadchiy V, Hsiao EY, Tap J, Derrien M, Gupta A, Tillisch K, Le Nevé B, Grinsvall C, Ljungberg M, Öhman L, Törnblom H, Simren M, Mayer EA. Evidence for an association of gut microbial Clostridia with brain functional connectivity and gastrointestinal sensorimotor function in patients with irritable bowel syndrome, based on tripartite network analysis. *Microbiome*. 2019 Mar 21;7(1):45.

265. Mavroudis G, Magnusson MK, Isaksson S, Sundin J, Simrén M, Öhman L, Strid H. Mucosal and systemic immune profiles differ during early and late phase of the disease in patients with active ulcerative colitis. *J Crohns Colitis*. 2019 Oct 28;13(11):1450-1458.
266. Le Nevé B, Derrien M, Tap J, Brazeilles R, Cools Portier S, Guyonnet D, Ohman L, Störsrud S, Törnblom H, Simrén M. Fasting breath H₂ and gut microbiota metabolic potential are associated with the response to a fermented milk product in irritable bowel syndrome. *PLoS One*. 2019 Apr 4;14(4):e0214273.
267. Josefsson A, Rosendahl A, Jerlstad P, Näslin G, Törnblom H, Simrén M. Visceral sensitivity remains stable over time in patients with irritable bowel syndrome, but with individual fluctuations. *Neurogastroenterol Motil*. 2019 Jul;31(7):e13603.
268. Simrén M, Törnblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J. Cumulative Effects of Psychologic Distress, Visceral Hypersensitivity, and Abnormal Transit on Patient-reported Outcomes in Irritable Bowel Syndrome. *Gastroenterology*. 2019 Aug;157(2):391-402.e2.
269. Midenfjord I, Polster A, Sjövall H, Törnblom H, Simrén M. Anxiety and depression in irritable bowel syndrome: Exploring the interaction with other symptoms and pathophysiology using multivariate analyses. *Neurogastroenterol Motil*. 2019 Aug;31(8):e13619.
270. Tack J, Stanghellini V, Mearin F, Yiannakou Y, Layer P, Coffin B, Simren M, Mackinnon J, Wiseman G, Marciniak A; IBIS-C Study group. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. *BMC Gastroenterol*. 2019 May 7;19(1):69.
271. Whitehead WE, Simren M, Busby-Whitehead J, Heymen S, van Tilburg MAL, Sperber AD, Palsson O. Fecal Incontinence Diagnosed by the Rome IV Criteria in the United States, Canada, and the United Kingdom. *Clin Gastroenterol Hepatol*. 2020 Feb;18(2):385-391.
272. Ekerfors U, Sunnerhagen KS, Westin J, Jakobsson Ung E, Marschall HU, Josefsson A, Simrén M. Muscle performance and fatigue in compensated chronic liver disease. *Scand J Gastroenterol*. *Scand J Gastroenterol*. 2019 Jul;54(7):925-933.
273. Björkman I, Ringström G, Simrén M, Myrgren J, Jakobsson Ung E. An Intervention for Person-Centered Support in Irritable Bowel Syndrome: Development and Pilot Study. *Gastroenterol Nurs*. 2019 Jul/Aug;42(4):332-341.
274. Clevers E, Törnblom H, Simrén M, Tack J, Van Oudenhove L. Relations between food intake, psychological distress, and gastrointestinal symptoms: A diary study. *United European Gastroenterol J*. 2019 Aug;7(7):965-973.
275. Rej A, Aziz I, Tornblom H, Sanders DS, Simrén M. The role of diet in irritable bowel syndrome: implications for dietary advice. *J Intern Med*. 2019 Nov;286(5):490-502.
276. Algera J, Colomier E, Simrén M. The Dietary Management of Patients with Irritable Bowel Syndrome: A Narrative Review of the Existing and Emerging Evidence. *Nutrients*. 2019 Sep 9;11(9). pii: E2162. nu11092162.

277. Sundin J, Nordlander S, Eutamene H, Alquier-Bacque V, Cartier C, Theodorou V, Le Nevé B, Törnblom H, Simrén M, Öhman L. Colonic mast cell numbers, symptom profile, and mucosal expression of elements of the epithelial barrier in irritable bowel syndrome. *Neurogastroenterol Motil.* 2019 Nov;31(11):e13701
278. Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G, Hungin APS, Layer P, Mendive JM, Pfeifer J, Rogler G, Scott SM, Simrén M, Whorwell P; Functional Constipation Guidelines Working Group. European society of neurogastroenterology and motility guidelines on functional constipation in adults. *Neurogastroenterol Motil.* 2020 Feb;32(2):e13762
279. Jakobsson S, Ringström G, Andersson E, Eliasson B, Johannsson G, Simrén M, Jakobsson Ung E. Patient safety before and after implementing person-centred inpatient care - A quasi-experimental study. *J Clin Nurs.* 2020 Feb;29(3-4):602-612.
280. Klingberg E, Magnusson MK, Strid H, Deminger A, Ståhl A, Sundin J, Simrén M, Carlsten H, Öhman L, Forsblad-d'Elia H. A distinct gut microbiota composition in patients with ankylosing spondylitis is associated with increased levels of fecal calprotectin. *Arthritis Res Ther.* 2019 Nov 27;21(1):248
281. Ryhlander J, Ringstrom G, Simrén M, Stotzer PO, Jakobsson S. Undergoing repeated colonoscopies - experiences from patients with inflammatory bowel disease. *Scand J Gastroenterol.* 2019 Dec;54(12):1467-1472.
282. Aziz I, Whitehead WE, Palsson OS, Törnblom H, Simrén M. An approach to the diagnosis and management of Rome IV functional disorders of chronic constipation. *Expert Rev Gastroenterol Hepatol.* 2020 Jan;14(1):39-46.
283. Moraes L, Magnusson MK, Mavroudis G, Polster A, Jonefjäll B, Törnblom H, Sundin J, Simrén M, Strid H, Öhman L. Systemic Inflammatory Protein Profiles Distinguish Irritable Bowel Syndrome (IBS) and Ulcerative Colitis, Irrespective of Inflammation or IBS-Like Symptoms. *Inflamm Bowel Dis.* 2020 May 12;26(6):874-884.
284. Palsson OS, Whitehead W, Törnblom H, Sperber AD, Simren M. Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom. *Gastroenterology.* 2020 Apr;158(5):1262-1273.e3
285. Sundin J, Aziz I, Nordlander S, Polster A, Hu YOO, Hugerth LW, Pennhag AAL, Engstrand L, Törnblom H, Simrén M, Öhman L. Evidence of altered mucosa-associated and fecal microbiota composition in patients with Irritable Bowel Syndrome. *Sci Rep.* 2020 Jan 17;10(1):593.
286. Clevers E, Nordqvist A, Törnblom H, Tack J, Masclee A, Keszthelyi D, Van Oudenhove L, Simrén M. Food-symptom diaries can generate personalized lifestyle advice for managing gastrointestinal symptoms: A pilot study. *Neurogastroenterol Motil.* 2020 Aug;32(8):e13820.
287. Clevers E, Tran M, Van Oudenhove L, Störsrud S, Böhn L, Törnblom H, Simrén M. Adherence to diet low in fermentable carbohydrates and traditional diet for irritable bowel syndrome. *Nutrition.* May;73:110719.

288. Lam CY, Palsson OS, Whitehead WE, Sperber AD, Tornblom H, Simren M, Aziz I. Rome IV Functional Gastrointestinal Disorders and Health Impairment in Subjects With Hypermobility Spectrum Disorders or Hypermobile Ehlers-Danlos Syndrome. *Clin Gastroenterol Hepatol*. 2021 Feb;19(2):277-287.e3.
289. Moayyedi P, Simrén M, Bercik P. Evidence-based and mechanistic insights into exclusion diets for IBS. *Nat Rev Gastroenterol Hepatol*. 2020 Jul;17(7):406-413.
290. McCulloch SM, Aziz I, Polster AV, Pischel AB, Stålsmeden H, Shafazand M, Block M, Byr öd G, Lindkvist B, Törnblom H, Jonefjäll B, Simren M. The diagnostic value of a change in bowel habit for colorectal cancer within different age groups. *United European Gastroenterol J*. 2020 Mar;8(2):211-219.
291. Lindfors P, Axelsson E, Engstrand K, Störsrud S, Jerlstad P, Törnblom H, Ljótsson B, Simrén M, Ringström G. Online Education Is Non-Inferior to Group Education for Irritable Bowel Syndrome: A Randomized Trial and Patient Preference Trial. *Clin Gastroenterol Hepatol*. 2021 Apr;19(4):743-751.e1.
292. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrescu DL, Fang X, Fukudo S, Kellow J, Okeke E, Quigley EM, Schmulson M, Whorwell P, Archampong T, Adibi P, Andresen V, Benninga MA, Bonaz B, Bor S, Fernandez LB, Choi SC, Corazziari ES, Francisconi C, Hani A, Lazebnik L, Lee YY, Mulak A, Rahman MM, Santos J, Setshedi M, Syam AF, Vanner S, Wong RK, Lopez-Colombo A, Costa V, Dickman R, Kanazawa M, Keshteli AH, Khatun R, Maleki I, Poitras P, Pratap N, Stefanyuk O, Thomson S, Zeevenhooven J, Palsson OS. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. *Gastroenterology*. 2021 Jan;160(1):99-114.e3.
293. Ahluwalia B, Magnusson MK, Böhn L, Störsrud S, Larsson F, Savolainen O, Ross A, Simrén M, Öhman L. Randomized Clinical Trial: Effects of Aloe Barbadensis Mill. Extract on Symptoms, Fecal Microbiota and Fecal Metabolite Profiles in Patients With Irritable Bowel Syndrome. *Neurogastroenterol Motil*. 2020 Aug;32(8):e13860
294. Sjölund J, Uusijärvi A, Tornkvist NT, Kull I, Bergström A, Alm J, Törnblom H, Olen O, Simrén M. Prevalence and Progression of Recurrent Abdominal Pain, From Early Childhood to Adolescence. *Clin Gastroenterol Hepatol*. 2021 May;19(5):930-938.e8.
295. Strömbeck A, Lasson A, Strid H, Sundin J, Stotzer PO, Simrén M, Magnusson MK, Öhman L. Fecal Microbiota Composition Is Linked to the Postoperative Disease Course in Patients With Crohn's Disease. *BMC Gastroenterol*. 2020 May 4;20(1):130.
296. Tack J, Schol J, Geeraerts A, Huang IH, Mori H, Scarpellini E, Sinonquel P, Carbone F, Colomier E, Geysen H, Jandee S, Moonen A, Pannemans J, Timmermans L, Van den Houte K, Verbeure W, Wauters L, Bisschops R, Hoffman I, Roelandt P, Rommel N, Simren M, Suzuki H, Tornblom H, Verbeke K, Vanuytsel T. A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for

- recommencing activities in the early recovery phase. *Neurogastroenterol Motil.* 2020 Jul;32(7):e13926.
297. Iribarren C, Törnblom H, Aziz I, Magnusson MK, Sundin J, Vigsnaes LK, Amundsen ID, McConnell B, Seitzberg D, Öhman L, Simrén M. Human milk oligosaccharide supplementation in irritable bowel syndrome patients: A parallel, randomized, double-blind, placebo-controlled study. *Neurogastroenterol Motil.* 2020 Oct;32(10):e13920.
298. Midenfjord I, Polster A, Sjövall H, Friberg P, Törnblom H, Simrén M. Associations among neurophysiology measures in irritable bowel syndrome (IBS) and their relevance for IBS symptoms. *Sci Rep.* 2020 Jun 17;10(1):9794.
299. Bajaj JS, Brenner DM, Cai Q, Cash BD, Crowell M, DiBaise J, Gallegos-Orozco JF, Gardner TB, Gyawali CP, Ha C, Holtmann G, Jamil LH, Kaplan GG, Karsan HA, Kinoshita Y, Lebwohl B, Leontiadis GI, Lichtenstein GR, Longstreth GF, Muthusamy VR, Oxentenko AS, Pimentel M, Pisegna JR, Rubenstein JH, Russo MW, Saini SD, Samadder NJ, Shaukat A, Simren M, Stevens T, Valdovinos M, Vargas H, Spiegel B, Lacy BE. Major Trends in Gastroenterology and Hepatology Between 2010 and 2019: An Overview of Advances From the Past Decade Selected by the Editorial Board of The American Journal of Gastroenterology. *Am J Gastroenterol.* 2020 Jul;115(7):1007-1018..
300. Kano M, Grinsvall C, Ran Q, Dupont P, Morishita J, Muratsubaki T, Mugikura S, Ly HG, Törnblom H, Ljungberg M, Takase K, Simrén M, Van Oudenhove L, Fukudo S. Resting state functional connectivity of the pain matrix and default mode network in irritable bowel syndrome: a graph theoretical analysis. *Sci Rep.* 2020 Jul 3;10(1):11015.
301. Vork L, Keszthelyi D, van Kuijk SMJ, Quetglas EG, Törnblom H, Simrén M, Aziz Q, Corsetti M, Tack J, Mujagic Z, Leue C, Kruimel JW, Masclee AAM. Patient-Specific Stress-Abdominal Pain Interaction in Irritable Bowel Syndrome: An Exploratory Experience Sampling Method Study. *Clin Transl Gastroenterol.* 2020 Jul;11(7):e00209.
302. Tai FWD, Palsson OS, Lam CY, Whitehead WE, Sperber AD, Tornblom H, Simren M, Aziz I. Functional gastrointestinal disorders are increased in joint hypermobility-related disorders with concomitant postural orthostatic tachycardia syndrome. *Neurogastroenterol Motil.* 2020 Dec;32(12):e13975.
303. Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G, Hungin APS, Layer P, Mendive JM, Pfeifer J, Rogler G, Scott M, Simrén M, Whorwell P. Responses to the Letter to the Editor by Brusciano et al. *Neurogastroenterol Motil.* 2020 Sep;32(9):e13981.
304. Mavroudis G, Strid H, Jonefjäll B, Simrén M. Visceral hypersensitivity is together with psychological distress and female gender associated with severity of IBS-like symptoms in quiescent ulcerative colitis. *Neurogastroenterol Motil.* 2020 Oct 9;e13998.
305. Sifrim D, Roman S, Savarino E, Bor S, Bredenoord AJ, Castell D, Cicala M, de Bortoli N, Frazzoni M, Gonlachanvit S, Iwakiri K, Kawamura O, Krarup A, Lee YY, Soon Ngiu C, Ndebia E, Patcharatraku T, Pauwels A, Pérez de la Serna J, Ramos R, Remes-Troche JM, Ribolsi M, Sammon A, Simren M, Tack J, Tutuian R, Valdovinos M, Xiao Y, Zerbib F,

- Gyawali CP. Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. *Gut*. 2020 Oct 9; Online ahead of print.
306. Simrén M, Tack J. Combining symptoms and biomarkers: The future diagnostic approach for disorders of gut-brain interaction? *Neurogastroenterol Motil*. 2020 Nov;32(11):e14019.
307. Midenfjord I, Borg A, Törnblom H, Simrén M. Cumulative Effect of Psychological Alterations on Gastrointestinal Symptom Severity in Irritable Bowel Syndrome. *Am J Gastroenterol*. 2021 Apr;116(4):769-779
308. Grinsvall C, Ryu HJ, Van Oudenhove L, Labus JS, Gupta A, Ljungberg M, Törnblom H, Mayer EA, Simrén M. Association between pain sensitivity and gray matter properties in the sensorimotor network in women with irritable bowel syndrome. *Neurogastroenterol Motil*. 2021 Apr;33(4):e14027.
309. Jabbar KS, Dolan B, Eklund L, Wising C, Ermund A, Johansson Å, Törnblom H, Simren M, Hansson GC. Association between Brachyspira and irritable bowel syndrome with diarrhoea. *Gut* 2021 Jun;70(6):1117-1129.
310. Aziz I, Simrén M. The overlap between irritable bowel syndrome and organic gastrointestinal diseases. *Lancet Gastroenterol Hepatol*. 2021 Feb;6(2):139-148
311. Melchior C, Simrén M. Positive Effect of Bimodal Release Ondansetron in Irritable Bowel Syndrome With Diarrhea: Relevance of Low-Grade Inflammation? *Am J Gastroenterol* 2020 Dec;115(12):1976-1978
312. Scott SM, Simrén M, Farmer AD, Dinning PG, Carrington EV, Benninga MA, Burgell RE, Dimidi E, Fikree A, Ford AC, Fox M, Hoad CL, Knowles CH, Krogh K, Nugent K, Remes-Troche JM, Whelan K, Corsetti M. Chronic constipation in adults: Contemporary perspectives and clinical challenges. 1: Epidemiology, diagnosis, clinical associations, pathophysiology and investigation. *Neurogastroenterol Motil*. 2021 Jun;33(6):e14050.
313. Nybacka S, Störsrud S, Lindqvist HM, Törnblom H, Simrén M, Winkvist A. Habitual FODMAP Intake in Relation to Symptom Severity and Pattern in Patients with Irritable Bowel Syndrome. *Nutrients*. 2020 Dec 23;13(1):27.
314. Palsson OS, Peery A, Seitzberg D, Amundsen ID, McConnell B, Simrén M. Human Milk Oligosaccharides Support Normal Bowel Function and Improve Symptoms of Irritable Bowel Syndrome: A Multicenter, Open-Label Trial. *Clin Transl Gastroenterol*. 2020 Dec;11(12):e00276.
315. Corsetti M, Brown S, Chiarioni G, Dimidi E, Dudding T, Emmanuel A, Fox M, Ford AC, Giordano P, Grossi U, Henderson M, Knowles CH, O'Connell PR, Quigley EMM, Simren M, Spiller R, Whelan K, Whitehead WE, Williams AB, Scott SM. Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment. *Neurogastroenterol Motil*. 2021 Jul;33(7):e14070.
316. Böhn L, Törnblom H, Van Oudenhove L, Simrén M, Störsrud S. A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on

- gastrointestinal symptoms in irritable bowel syndrome patients. *Neurogastroenterol Motil.* 2021 Jul;33(7):e14094.
317. Tap J, Störsrud S, Le Nevé B, Cotillard A, Pons N, Doré J, Öhman L, Törnblom H, Derrien M, Simrén M. Diet and gut microbiome interactions of relevance for symptoms in irritable bowel syndrome. *Microbiome* 2021 Mar 26;9(1):74.
318. Polster A, Öhman L, Tap J, Derrien M, Le Nevé B, Sundin J, Törnblom H, Cvijovic M, Simrén M. A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome. *Sci Rep* 2021;11(1):5521
319. Bosman M, Elsenbruch S, Corsetti M, Tack J, Simrén M, Winkens B, Boumans T, Masclée A, Keszthelyi D. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. *Lancet Gastroenterol Hepatol.* 2021 Jun;6(6):459-473.
320. Midenfjord I, Grinsvall C, Koj P, Carnerup I, Törnblom H, Simrén M. Central sensitization and severity of gastrointestinal symptoms in irritable bowel syndrome, chronic pain syndromes, and inflammatory bowel disease. *Neurogastroenterol Motil.* 2021 Dec;33(12):e14156.
321. Öhman L, Lasson A, Strömbeck A, Isaksson S, Hesselmar M, Simrén M, Strid H, Magnusson MK. Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis. *Sci Rep.* 2021 Apr 21;11(1):8641.
322. Klaassen T, Smeets FGM, Vork L, Tack J, Talley NJ, Simrén M, Aziz Q, Ford AC, Kruimel JW, Conchillo JM, Leue C, Masclée AAM, Keszthelyi D. Psychometric evaluation of an experience sampling method-based patient-reported outcome measure in functional dyspepsia. *Neurogastroenterol Motil.* 2021 Sep;33(9):e14136.
323. Sperber AD, Freud T, Aziz I, Palsson OS, Drossman DA, Dumitrescu DL, Fang X, Fukudo S, Ghoshal UC, Kellow J, Khatun R, Okeke E, Quigley EM, Schmulson M, Simren M, Tack J, Whitehead WE, Whorwell P, Bangdiwala SI. Greater overlap of Rome IV disorders of gut-brain interactions leads to increased disease severity and poorer quality of life. *Clin Gastroenterol Hepatol.* 2022 May;20(5):e945-e956
324. Störsrud S, Böhn L, Törnblom H, Van Oudenhove L, Simrén M. Reply: The key to success: Targeting enzymes to their dietary counterpart. *Neurogastroenterol Motil.* 2021 Jul;33(7):e14203.
325. Mohr S, Fritz N, Hammer C, Martínez C, Berens S, Schmitteckert S, Wahl V, Schmidt M, Houghton LA, Goebel-Stengel M, Kabisch M, Götze D, Milovač I, D'Amato M, Zheng T, Röth R, Mönnikes H, Engel F, Gauss A, Tesarz J, Raithel M, Andresen V, Frieling T, Keller J, Pehl C, Stein-Thöringer C, Clarke G, Kennedy PJ, Cryan JF, Dinan TG, Quigley EMM, Spiller R, Beltrán C, Madrid AM, Torres V, Pérez de Arce E, Herzog W, Mayer EA, Sayuk G, Gazouli M, Karamanolis G, Kapur-Pojskič L, Bustamante M, Rabionet R, Estivil X, Franke A, Lieb W, Boeckxstaens G, Wouters MM, Simrén M, Rappold GA, Vicario M, Santos J, Schaefer R, Lorenzo-Bermejo J, Niesler B. The alternative serotonin transporter promoter

- P2 impacts gene function in females with irritable bowel syndrome. *J Cell Mol Med.* 2021 Aug;25(16):8047-8061.
326. Ahluwalia B, Iribarren C, Magnusson MK, Sundin J, Clevers E, Savolainen O, Ross AB, Törnblom H, Simrén M, Öhman L. A Distinct Faecal Microbiota and Metabolite Profile Linked to Bowel Habits in Patients with Irritable Bowel Syndrome. *Cells.* 2021;10(6):1459.
327. Melchior C, Algera J, Colomier E, Törnblom H, Simrén M, Störsrud S. Food avoidance and restriction in irritable bowel syndrome: relevance for symptoms, quality of life and nutrient intake. *Clin Gastroenterol Hepatol.* 2022 Jun;20(6):1290-1298.e4.
328. Parker S, Palsson O, Sanders DS, Simren M, Sperber AD, Törnblom H, Urwin H, Whitehead W, Aziz I. Functional Gastrointestinal Disorders and Associated Health Impairment in Individuals with Celiac Disease. *Clin Gastroenterol Hepatol.* 2022 Jun;20(6):1315-1325.e4.
329. Sjölund J, Kull I, Bergström A, Järås J, Ludvigsson JF, Törnblom H, Simrén M, Olén O. Allergy-related diseases in childhood and risk for abdominal pain-related functional gastrointestinal disorders at 16 years-a birth cohort study. *BMC Med.* 2021 Sep 16;19(1):214.
330. Algera JP, Störsrud S, Lindström A, Simrén M, Törnblom H. Gluten and fructan intake and their associations with gastrointestinal symptoms in irritable bowel syndrome: A food diary study. *Clin Nutr.* 2021 Oct;40(10):5365-5372.
331. Tornkvist NT, Aziz I, Whitehead WE, Sperber AD, Palsson OS, Hreinsson JP, Simrén M, Törnblom H. Health care utilization of individuals with Rome IV irritable bowel syndrome in the general population. *United European Gastroenterol J.* 2021 Dec;9(10):1178-1188
332. Nybacka S, Simrén M, Störsrud S, Törnblom H, Winkvist A, Lindqvist HM. Changes in serum and urinary metabolomic profile after a dietary intervention in patients with irritable bowel syndrome *PLoS One.* 2021 Oct 11;16(10):e0257331.
333. Ahluwalia B, Magnusson MK, Böhn L, Störsrud S, Larsson F, Öhman L, Simrén M. Aloe barbadensis Mill. extract improves symptoms in IBS patients with diarrhoea: post hoc analysis of two randomized double-blind controlled studies. *Therap Adv Gastroenterol.* 2021 Oct 8;14:17562848211048133.
334. Eijsbouts C, Zheng T, Kennedy NA, Bonfiglio F, Anderson CA, Moutsianas L, Holliday J, Shi J, Shringarpure S; 23andMe Research Team, Voda AI; Bellygenes Initiative, Farrugia G, Franke A, Hübenthal M, Abecasis G, Zawistowski M, Skogholt AH, Ness-Jensen E, Hveem K, Esko T, Teder-Laving M, Zhernakova A, Camilleri M, Boeckxstaens G, Whorwell PJ, Spiller R, McVean G, D'Amato M, Jostins L, Parkes M. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. *Nat Genet.* 2021 Nov;53(11):1543-1552.
335. Marasco G, Cremon C, Barbaro MR, Salvi D, Cacciari G, Kagramanova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ,

- Koc ES, Sirin G, Caliskan AR, Bengi G, Alis EE, Lukic S, Trajkovska M, Hod K, Dumitrescu D, Pietrangelo A, Corradini E, Simren M, Sjolund J, Tornkvist N, Ghoshal UC, Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, Danese S, Portincasa P, Di Stefano M, Maggio M, Philippou E, Lee YY, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; and the GI-COVID19 Study Group. Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study. *Am J Gastroenterol*. 2022 Jan 1;117(1):147-157.
336. Josefsson A, Hreinsson JP, Simrén M, Tack J, Bangdiwala SI, Sperber AD, Palsson OS, Törnblom H. Global prevalence and impact of Rumination syndrome. *Gastroenterology*. 2022 Mar;162(3):731-742.e9
337. Iribarren C, Magnusson MK, Vigsnæs LK, Aziz I, Amundsen ID, Šuligoj T, Juge N, Patel P, Sapnara M, Johnsen L, Sørensen N, Sundin J, Törnblom H, Simrén M, Öhman L. The Effects of Human Milk Oligosaccharides on Gut Microbiota, Metabolite Profiles and Host Mucosal Response in Patients with Irritable Bowel Syndrome. *Nutrients*. 2021 Oct 27;13(11):3836.
338. Grinsvall C, Van Oudenhove L, Dupont P, Ryu HJ, Ljungberg M, Labus JS, Törnblom H, Mayer EA, Simrén M. Altered Structural Covariance of Insula, Cerebellum and Prefrontal Cortex Is Associated with Somatic Symptom Levels in Irritable Bowel Syndrome (IBS). *Brain Sci*. 2021 Nov 29;11(12):1580.
339. Bonfiglio F, Liu X, Smillie C, Pandit A, Kurilshikov A, Bacigalupo R, Zheng T, Nim H, Garcia-Etxebarria K, Bujanda L, Andreasson A, Agreus L, Walter S, Abecasis G, Eijsbouts C, Jostins L, Parkes M, Hughes DA, Timpson N, Raes J, Franke A, Kennedy NA, Regev A, Zhernakova A, Simren M, Camilleri M, D'Amato M. GWAS of stool frequency provides insights into gastrointestinal motility and irritable bowel syndrome. *Cell Genom*. 2021 Dec 8;1(3):None. doi: 10.1016/j.xgen.2021.100069.
340. Nybacka S, Törnblom H, Simren M, Störsrud S. The Role of Carbohydrates in Irritable Bowel Syndrome: Protocol for a Randomized Controlled Trial Comparing Three Different Treatment Options. *JMIR Res Protoc*. 2022 Jan 17;11(1):e31413.
341. Colomier E, Van Oudenhove L, Tack J, Böhn L, Bennet S, Nybacka S, Störsrud S, Öhman L, Törnblom H, Simrén M. Predictors of Symptom-Specific Treatment Response to Dietary Interventions in Irritable Bowel Syndrome. *Nutrients*. 2022 Jan 17;14(2):397.
342. Trindade IA, Melchior C, Colomier E, Algera J, Törnblom H, Simrén M. Letter in response to Black et al. (2020). *Neurogastroenterol Motil*. 2022 Jun;34(6):e14329.
343. Lacy BE, Crowell MD, Cangemi DJ, Lunsford TN, Simren M, Tack J. Diagnostic Evaluation of Gastric Motor and Sensory Disorders. *Am J Gastroenterol*. 2021 Dec;116(12):2345-2356.
344. Colomier E, Melchior C, Algera JP, Hreinsson JP, Störsrud S, Törnblom H, Van Oudenhove L, Palsson OS, Bangdiwala SI, Sperber AD, Tack J, Simrén M. Global prevalence and burden of meal-related abdominal pain. *BMC Med*. 2022 Feb 17;20(1):71.

345. Mavroudis G, Simrén M, Öhman L, Strid H. Health-related quality of life in patients with long-standing ulcerative colitis in remission. *Therap Adv Gastroenterol*. 2022 Feb 11;15:17562848211062406. eCollection 2022.
346. Frändemark Å, Törnblom H, Simrén M, Jakobsson S. Maintaining work life under threat of symptoms: a grounded theory study of work life experiences in persons with Irritable Bowel Syndrome. *BMC Gastroenterol*. 2022 Feb 19;22(1):73.
347. Törnblom H, Tsoposidis A, Wallenius V, Kostic S, Axelsson H, Lundell L, Håkanson B, Simrén M, Thorell A. Management of patients with gastroesophageal reflux disease can be optimized. *Lakartidningen*. 2022 Apr 22;119:21177.
348. Iribarren C, Nordlander S, Sundin J, Isaksson S, Savolainen O, Törnblom H, Magnusson MK, Simrén M, Öhman L. Fecal luminal factors from patients with irritable bowel syndrome induce distinct gene expression of colonoids. *Neurogastroenterol Motil*. 2022 Oct;34(10):e14390.
349. Lövdahl J, Törnblom H, Ringström G, Palsson OS, Simrén M. Randomised clinical trial: individual versus group hypnotherapy for irritable bowel syndrome. *Aliment Pharmacol Ther*. 2022 Jun;55(12):1501-1511.
350. Van den Houte K, Bercik P, Simren M, Tack J, Vanner S. Mechanisms underlying food-triggered symptoms in disorders of gut-brain interactions. *Am J Gastroenterol*. 2022 Jun 1;117(6):937-946.
351. Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. *J Psychosom Res*. 2022 Aug;159:110809.
352. Lövdahl J, Törnblom H, Ringstrom G, Palsson OS, Simrén M. Editorial: group-based hypnotherapy as good as individually delivered hypnotherapy for symptoms of irritable bowel syndrome-authors' reply. *Aliment Pharmacol Ther*. 2022 Jul;56(1):160-161.
353. Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrescu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility. *United European Gastroenterol J*. 2022 Jul;10(6):556-584.
354. Melchior C, Algera J, Colomier E, Törnblom H, Simrén M. Irritable bowel syndrome with food-related symptoms: Future directions in the clinical management. *United European Gastroenterol J*. 2022 Jul;10(6):594-600.
355. Simons J, Shajee U, Palsson O, Simren M, Sperber AD, Törnblom H, Whitehead W, Aziz I. Disorders of gut-brain interaction: Highly prevalent and burdensome yet under-taught within medical education. *United European Gastroenterol J*. 2022 Sep;10(7):736-744.

356. Berens S, Dong Y, Fritz N, Walstab J, D'Amato M, Zheng T, Wahl V, Boekstegers F, Bermejo JL, Martinez C, Schmitteckert S, Clevers E, Engel F, Gauss A, Herzog W, Spiller R, Goebel-Stengel M, Mönnikes H, Andresen V, Thomas F, Keller J, Pehl C, Stein-Thöringer C, Clarke G, Dinan TG, Quigley EM, Sayuk G, Simrén M, Tesarz J, Rappold G, van Oudenhove L, Schaefer R, Niesler B. Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study. *World J Gastroenterol.* 2022 Jun 7;28(21):2334-2349.
357. Melchior C, Colomier E, Trindade IA, Khadija M, Hreinsson JP, Törnblom H, Simrén M. Irritable bowel syndrome: Factors of importance for disease-specific quality of life. *United European Gastroenterol J.* 2022 Sep;10(7):754-764.
358. Moraes Holst L, Halfvarson J, Carlson M, Hedin C, Kruse R, Lindqvist CM, Bergemalm D, Almér S, Bresso F, Ling Lundström M, Repsilber D, D'Amato M, Keita Å, Hjortswang H, Söderholm J, Sundin J, Törnblom H, Simrén M, Strid H, Magnusson MK, Öhman L. Downregulated Mucosal Autophagy, Alpha Kinase-1 and IL-17 Signaling Pathways in Active and Quiescent Ulcerative Colitis. *Clin Exp Gastroenterol.* 2022 Jul 27;15:129-144.
359. Castro Tejera V, Öhman L, Aabakken L, Fellström B, Hausken T, Hovde Ø, Hreinsson JP, Lindberg G, Venge P, Simrén M, Törnblom H. Randomised clinical trial and meta-analysis: mesalazine treatment in irritable bowel syndrome-effects on gastrointestinal symptoms and rectal biomarkers of immune activity. *Aliment Pharmacol Ther.* 2022 Sep;56(6):968-979.
360. Huang IH, Schol J, Khatun R, Carbone F, Van den Houte K, Colomier E, Balsiger LM, Törnblom H, Vanuytsel T, Sundelin E, Simrén M, Palsson OS, Bangdiwala SI, Sperber AD, Tack J. Worldwide prevalence and burden of gastroparesis-like symptoms as defined by the United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on gastroparesis. *United European Gastroenterol J.* 2022 Oct;10(8):888-897.
361. Iribarren C, Maasfeh L, Öhman L, Simrén M. Modulating the gut microenvironment as a treatment strategy for irritable bowel syndrome: a narrative review. *Gut Microbiome.* 2022;3:e7,1-40
362. Hagström H, Simrén M, Ekbom A. In memoriam: Rolf Hultcrantz (1949-2022). *United European Gastroenterol J.* 2022 Oct;10(8):898.
363. Algera JP, Törnblom H, Simrén M. Treatments targeting the luminal gut microbiota in patients with irritable bowel syndrome. *Curr Opin Pharmacol.* 2022 Oct;66:102284..
364. Fritz N, Berens S, Dong Y, Martínez C, Schmitteckert S, Houghton LA, Goebel-Stengel M, Wahl V, Kabisch M, Götze D, D'Amato M, Zheng T, Röth R, Mönnikes H, Tesarz J, Engel F, Gauss A, Raithel M, Andresen V, Keller J, Frieling T, Pehl C, Stein-Thöringer C, Clarke G, Kennedy PJ, Cryan JF, Dinan TG, Quigley EMM, Spiller R, Beltrán C, Madrid AM, Torres V, Mayer EA, Sayuk G, Gazouli M, Karamanolis G, Bustamante M, Estivil X, Rabionet R, Hoffmann P, Nöthen MM, Heilmann-Heimbach S, Schmidt B, Franke A, Lieb W, Herzog W, Boeckxstaens G, Wouters MM, Simrén M, Rappold GA, Vicario M, Santos J, Schaefer R,

- Lorenzo-Bermejo J, Niesler B. The serotonin receptor 3E variant is a risk factor for female IBS-D. *J Mol Med (Berl)*. 2022 Nov;100(11):1617-1627.
365. Bosman M, Smeets F, Elsenbruch S, Tack J, Simrén M, Talley N, Winkens B, Masclee A, Keszthelyi D. Placebo response in pharmacological trials in patients with functional dyspepsia-A systematic review and meta-analysis. *Neurogastroenterol Motil*. 2023 Feb;35(2):e14474.
366. Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Randomised controlled trial: effects of gluten-free diet on symptoms and the gut microenvironment in irritable bowel syndrome. *Aliment Pharmacol Ther*. 2022 Nov;56(9):1318-1327.
367. Algera JP, Colomier E, Melchior C, Hreinsson JP, Midenfjord I, Clevers E, Simrén M, Törnblom H. Associations between postprandial symptoms, hydrogen and methane production, and transit time in irritable bowel syndrome. *Neurogastroenterol Motil*. 2023 Feb;35(2):e14482.
368. Josefsson A, Törnblom H, Simrén M. Type of Rectal Barostat Protocol Affects Classification of Hypersensitivity and Prediction of Symptom Severity in Irritable Bowel Syndrome. *J Neurogastroenterol Motil*. 2022 Oct 30;28(4):630-641.
369. Melchior C, Wilpart K, Midenfjord I, Trindade IA, Törnblom H, Tack JF, Simrén M, Van Oudenhove L. Relationship Between Abuse History and Gastrointestinal and Extraintestinal Symptom Severity in Irritable Bowel Syndrome. *Psychosom Med*. 2022 Nov-Dec 01;84(9):1021-1033.
370. Algera JP, Magnusson MK, Öhman L, Störsrud S, Simrén M, Törnblom H. Editorial: gluten-free but not pain-free in IBS-authors' reply. *Aliment Pharmacol Ther*. 2022 Dec;56(11-12):1623-1624.
371. Algera JP, Demir D, Törnblom H, Nybacka S, Simrén M, Störsrud S. Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity: A randomized crossover trial. *Clin Nutr*. 2022 Dec;41(12):2792-2800.
372. Simrén M. Targeting the gut microenvironment in IBS to improve symptoms. *Nat Rev Gastroenterol Hepatol*. 2023 Feb;20(2):69-70.
373. Holst LM, Iribarren C, Sapnara M, Savolainen O, Törnblom H, Wettergren Y, Strid H, Simrén M, Magnusson MK, Öhman L. Fecal Luminal Factors from Patients with Gastrointestinal Diseases Alter Gene Expression Profiles in Caco-2 Cells and Colonoids. *Int J Mol Sci*. 2022 Dec 7;23(24):15505.
374. Marasco G, Cremon C, Barbaro MR, Cacciari G, Falangone F, Kagrananova A, Bordin D, Drug V, Miftode E, Fusaroli P, Mohamed SY, Ricci C, Bellini M, Rahman MM, Melcarne L, Santos J, Lobo B, Bor S, Yapali S, Akyol D, Sapmaz FP, Urun YY, Eskazan T, Celebi A, Kacmaz H, Ebik B, Binicier HC, Bugdayci MS, Yağcı MB, Pullukcu H, Kaya BY, Tureyen A, Hatemi İ, Koc ES, Sirin G, Calışkan AR, Bengi G, Alış EE, Lukic S, Trajkovska M, Hod K, Dumitrescu D, Pietrangelo A, Corradini E, Simren M, Sjölund J, Tornkvist N, Ghoshal UC,

- Kolokolnikova O, Colecchia A, Serra J, Maconi G, De Giorgio R, Danese S, Portincasa P, Di Sabatino A, Maggio M, Philippou E, Lee YY, Salvi D, Venturi A, Borghi C, Zoli M, Gionchetti P, Viale P, Stanghellini V, Barbara G; GI-COVID19 study group. Post COVID-19 irritable bowel syndrome. *Gut* 2023;72:484-492.
375. Tornkvist NT, Backman AS, Linder M, Altman M, Simrén M, Olén O, Törnblom H. Identification of irritable bowel syndrome in the Swedish National Patient Register: a validation study. *Scand J Gastroenterol*. 2023 Jul;58(7):709-717.
376. Algera JP, Demir D, Törnblom H, Nybacka S, Simrén M, Störsrud S. Reply - Letter to the editor: Low FODMAP diet reduces gastrointestinal symptoms in irritable bowel syndrome and clinical response could be predicted by symptom severity. *Clin Nutr*. 2023 Apr;42(4):611-612.
377. Hreinsson JP, Törnblom H, Tack J, Drossman DA, Whitehead WE, Bangdiwala SI, Sperber AD, Palsson OS, Simrén M. Factor analysis of the Rome IV criteria for major disorders of gut-brain interaction (DGBI) globally and across geographical, sex and age groups. *Gastroenterology*. 2023 Jun;164(7):1211-1222.
378. Hreinsson JP, Wong RKM, Tack J, Whorwell P, Benninga MA, Andresen V, Bonaz B, Choi SC, Corazziari ES, Santos J, Fukudo S, Kanazawa M, Fang X, Bangdiwala SI, Sperber AD, Palsson OS, Simrén M. A comparative study of disorders of gut-brain interaction in Western Europe and Asia based on the Rome foundation global epidemiology study. *Neurogastroenterol Motil*. 2023 Jun;35(6):e14566.
379. Jansson-Rehnberg AS, Borgfeldt C, Münch A, Graf W, Simrén M, Lindberg G, M Hellström P. Pharmacological treatment of idiopathic diarrhea. *Lakartidningen*. 2023 Mar 22;120:22117.
380. Broeders B, Devolder E, Jones M, Simrén M, Bangdiwala SI, Sperber AD, Palsson OS, Tack J. Epidemiology of disorders of gut-brain interaction in Belgium and differences between two language groups: Results from the Rome foundation global epidemiology study. *Neurogastroenterol Motil*. 2023 Jun;35(6):e14588.
381. Sperber AD, Bor S, Fang X, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, Whitehead WE, Dumitrescu DL, Fukudo S, Kellow J, Okeke E, Quigley EMM, Schmulson M, Whorwell P, Archampong T, Adibi P, Andresen V, Benninga MA, Bonaz B, Fernandez LB, Choi SC, Corazziari ES, Francisconi C, Hani A, Lazebnik L, Lee YY, Mulak A, Rahman MM, Santos J, Setshedi M, Syam AF, Vanner S, Wong RK, Lopez-Colombo A, Costa V, Dickman R, Kanazawa M, Keshteli AH, Khatun R, Maleki I, Poitras P, Pratap N, Stefanyuk O, Thomson S, Buyruk M, Unal N, Huang D, Song J, Hreinsson JP, Palsson OS. Face-to-face interviews versus Internet surveys: Comparison of two data collection methods in the Rome foundation global epidemiology study: Implications for population-based research. *Neurogastroenterol Motil*. 2023 Jun;35(6):e14583.

382. Tornkvist NT, Simrén M, Hreinsson JP, Tack J, Bangdiwala SI, Sperber AD, Palsson OS, Josefsson A, Törnblom H. Prevalence and impact of disorders of Gut-Brain interaction in Sweden. *Neurogastroenterol Motil.* 2023 Jun;35(6):e14578.
383. Alemany S, Soler-Artigas M, Cabana-Domínguez J, Fakhreddine D, Llonga N, Vilar-Ribó L, Rodríguez-Urrutia A, Palacio J, González-Castro AM, Lobo B, Alonso-Cotoner C, Simrén M, Santos J, Ramos-Quiroga JA, Ribasés M. Genome-wide multi-trait analysis of irritable bowel syndrome and related mental conditions identifies 38 new independent variants. *J Transl Med.* 2023 Apr 21;21(1):272.
384. Colomier E, Algera JP, Van den Houte K, Simrén M, Tack J. Mechanisms underlying food-related symptoms in disorders of gut-brain interaction: Course ahead in research and clinical practice. *Best Pract Res Clin Gastroenterol.* 2023 Feb-Mar;62-63:101824.
385. Frändemark Å, Törnblom H, Hreinsson JP, Andresen V, Benninga MA, Corazziari ES, Fukudo S, Mulak A, Santos J, Sperber AD, Bangdiwala SI, Palsson OS, Simrén M. Work productivity and activity impairment in disorders of gut-brain interaction: Data from the Rome Foundation Global Epidemiology Study. *United European Gastroenterol J.* 2023 Jul;11(6):503-513
386. Simrén M. Jan Tack awardee of the 2023 UEG Lifetime Achievement Award. *United European Gastroenterol J.* 2023 Sep;11(7):708-709.
387. Ekerfors U, Simrén M, Marschall HU, Demir D, Josefsson A. The influence of muscle performance and fatigue on prognosis in patients with compensated liver disease. *BMC Gastroenterol.* 2023 Sep 6;23(1):302.
388. Trindade IA, Hreinsson JP, Melchior C, Algera JP, Colomier E, Törnblom H, Drossman D, Tack J, Palsson OS, Bangdiwala SI, Sperber AD, Simrén M. Global prevalence of psychological distress and comorbidity with disorders of gut-brain interactions. *Am J Gastroenterol.* 2024 Jan 1;119(1):165-175.
389. Sjölund J, Kull I, Bergström A, Ljótsson B, Törnblom H, Olén O, Simrén M. Quality of Life and Bidirectional Gut-Brain Interactions in Irritable Bowel Syndrome From Adolescence to Adulthood. *Clin Gastroenterol Hepatol.* 2024 Apr;22(4):858-866.e6..
390. Busby-Whitehead J, Whitehead WE, Sperber AD, Palsson OS, Simrén M. The aging gut: Symptoms compatible with disorders of gut-brain interaction (DGBI) in older adults in the general population. *J Am Geriatr Soc.* 2024 Feb;72(2):479-489.
391. Elmunzer BJ, Palsson OS, Forbes N, Zakaria A, Davis C, Canakakis A, Qayed E, Bick B, Pawa S, Tierney WM, McLeod CG, Taylor J, Patel H, Mendelsohn RB, Bala G, Sloan I, Merchant AA, Smith ZL, Sendzishev Shane MA, Aroniadis OC, Ordiah CO, Ruddy JM, Simren M, Tack J, Drossman D; Rome Foundation Research Institute and the North American Alliance for the Study of Digestive Manifestations of COVID-19. Prolonged Gastrointestinal Manifestations After Recovery From COVID-19. *Clin Gastroenterol Hepatol.* 2024 May;22(5):1098-1107.e3

392. Josefsson A, Simrén M, Smolak A, Sabbagh N, Törnblom H. Natural history of symptoms and prognostic information of the rapid drink challenge and solid bolus swallows in esophagogastric junction outflow obstruction defined by manometry. *Neurogastroenterol Motil.* 2024 Feb;36(2):e14720.
393. Iribarren C, Savolainen O, Sapnara M, Törnblom H, Simrén M, Magnusson MK, Öhman L. Temporal stability of fecal metabolomic profiles in irritable bowel syndrome. *Neurogastroenterol Motil.* 2024 Mar;36(3):e14741
394. Balsiger LM, Tack J, Simrén M, van Gils T. Comments on the use of confocal laser endomicroscopy in diagnosing protein-losing enteropathy. *Endoscopy.* 2024 Feb;56(2):158.
395. Palsson OS, Tack J, Drossman DA, Le Nevé B, Quinquis L, Hassouna R, Ruddy J, Morris CB, Sperber AD, Bangdiwala SI, Simrén M. Worldwide population prevalence and impact of sub-diagnostic gastrointestinal symptoms. *Aliment Pharmacol Ther.* 2024 Apr;59(7):852-864.
396. Jansson-Rehnberg AS, Drewes AM, Sponheim J, Borgfelt C, Münch A, Graf W, Simrén M, Lindberg G, Hellström PM. Diarrhoea of unknown cause: medical treatment in a stepwise manner: Management of Idiopathic Diarrhoea Based on Experience of Step-Up Medical Treatment. *Scand J Gastroenterol.* 2024 May;59(5):543-546.
397. Mårlid K, Söderling J, Lebwohl B, Green PH, Törnblom H, Simrén M, Staller K, Olén O, Ludvigsson JF. Association between celiac disease and irritable bowel syndrome: a nationwide cohort study. *Clin Gastroenterol Hepatol.* 2024 Jul;22(7):1404-1415.e20.
398. Van Den Houte M, Guadagnoli L, Ohman L, Bergstedt A, Johansson BZ, Simren M, Strid H, Van Oudenhove L, Svedlund J. Predictors of symptom trajectory in newly diagnosed ulcerative colitis: a 3-year follow-up cohort study. *J Crohns Colitis.* 2024 Mar 29 Online ahead of print.
399. Nybacka S, Törnblom H, Josefsson A, Hreinsson JP, Böhn L, Frändemark Å, Weznaver C, Störsrud S, Simrén M. A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial. *Lancet Gastroenterol Hepatol.* 2024 Jun;9(6):507-520.
400. Clevers E, Launders D, Helme D, Nybacka S, Störsrud S, Corsetti M, Van Oudenhove L, Simrén M, Tack J. Coffee, Alcohol, and Artificial Sweeteners Have Temporal Associations with Gastrointestinal Symptoms. *Dig Dis Sci.* 2024 Jul;69(7):2522-2529
401. Goodoory VC, Khasawneh M, Thakur ER, Everitt HA, Gudleski GD, Lackner JM, Moss-Morris R, Simren M, Vasant DH, Moayyedi P, Black CJ, Ford AC. Effect of Brain-gut Behavioral Treatments on Abdominal Pain in Irritable Bowel Syndrome: Systematic Review and Network Meta-analysis. *Gastroenterology.* 2024 Oct;167(5):934-943.e5.
402. Kashyap P, Moayyedi P, Quigley EMM, Simren M, Vanner S. Critical appraisal of the SIBO hypothesis and breath testing: A clinical practice update endorsed by the European society

- of neurogastroenterology and motility (ESNM) and the American neurogastroenterology and motility society (ANMS). *Neurogastroenterol Motil.* 2024 Jun;36(6):e14817
403. Sperber AD, Freud T, Palsson OS, Bangdiwala SI, Simren M. The aging gastrointestinal tract: Epidemiology and clinical significance of disorders of gut-brain interaction in the older general population. *Aliment Pharmacol Ther.* 2024 Aug;60(4):446-456.
404. van Gils T, Hreinsson JP, Törnblom H, Tack J, Bangdiwala SI, Palsson OS, Sperber AD, Simrén M. Symptom profiles compatible with disorders of gut-brain interaction (DGBI) in organic gastrointestinal diseases: A global population-based study. *United European Gastroenterol J.* 2024 Sep;12(7):834-847.
405. Nybacka S, Törnblom H, Josefsson A, Hreinsson JP, Böhn L, Frändemark Å, Weznaver C, Störsrud S, Simrén M. Diet or optimised medical therapy for people with irritable bowel syndrome - Authors' reply. *Lancet Gastroenterol Hepatol.* 2024 Sep;9(9):786-787.
406. Weznaver C, Nybacka S, Simren M, Törnblom H, Jakobsson S, Störsrud S. Patients' experiences of dietary changes during a structured dietary intervention for irritable bowel syndrome. *J Hum Nutr Diet.* 2024 Oct;37(5):1336-1348
407. Algera JP, Blomsten A, Khadija M, Verbeke K, Vanuytsel T, Tack J, Simrén M, Törnblom H. Distinct age-related characteristics in patients with irritable bowel syndrome: patient reported outcomes and measures of gut physiology. *npj Gut and Liver* 2024 1:10
408. Simrén M. Diet Options for IBS Other Than the Low-FODMAP Diet. *Gastroenterol Hepatol (N Y).* 2024 Aug;20(5):297-299.
409. Sperber AD, Freud T, Palsson OS, Bangdiwala SI, Simren M. Letter: Social work and clinical synergy-Optimizing health interventions for elderly DGBI populations: Authors' reply. *Aliment Pharmacol Ther.* 2024 Oct;60(8):1145-1146.
410. Bosman M, Vork L, Jonkers D, Snijkers J, Topan R, Aziz Q, Midenfjord I, Simren M, Masclee A, Keszthelyi D; ESM study group. Results From a Psychometric Validation Study: Patients With Irritable Bowel Syndrome Report Higher Symptom Burden Using End-of-Day Vs Real-Time Assessment. *Am J Gastroenterol.* 2024 Sep 23. Online ahead of print.
411. Magnusson MK, Bas Forsberg A, Vurveda A, Sapnara M, Lorent J, Savolainen O, Wettergren Y, Strid H, Simrén M, Öhman L. Exposure of Colon-Derived Epithelial Monolayers to Fecal Luminal Factors from Patients with Colon Cancer and Ulcerative Colitis. *Int J Mol Sci.* 2024 Sep 13;25(18):9886.
412. Rajan A, Gallego P, Dolan B, Patel P, Dwibedi C, Luis AS, Trillo-Muyo S, Arike L, van der Post S, Simrén M, Pelaseyed T. BPP43_05035 is a *Brachyspira pilosicoli* cell surface adhesin that weakens the integrity of the epithelial barrier during infection. *Gut Microbes.* 2024 Jan-Dec;16(1):2409247.
413. van Gils T, Törnblom H, Hreinsson JP, Jonefjäll B, Strid H, Simrén M. Factors Associated With Abdominal Pain in Patients With Active and Quiescent Ulcerative Colitis: A Multicohort Study. *Aliment Pharmacol Ther.* 2025 Jan;61(2):268-277.

414. van Gils T, Törnblom H, Hreinsson JP, Jonefjäll B, Strid H, Simrén M. Editorial: Understanding Factors Associated With Abdominal Pain in Ulcerative Colitis-No Surprises but the Usual Suspects Need Greater Attention. Authors' Reply. *Aliment Pharmacol Ther.* 2025 Jan;61(2):373-374.
415. Nybacka S, Colomier E, Páll Hreinsson J, Störsrud S, Tack J, Törnblom H, Simrén M. Dietary Intake and Quality in Irritable Bowel Syndrome: A Comparative Study With Controls and the Association With Symptom Severity. *Am J Gastroenterol.* 2024 Nov 27. Online ahead of print.
416. Venge P, Tejera VC, Petersson C, Xu S, Larsson A, Simrén M, Öhman L, Törnblom H. Elevated Fecal Biomarkers of Colo-Rectal Epithelial Cell Activity in Irritable Bowel Syndrome. *Neurogastroenterol Motil.* 2024 Dec 17:e14984. Epub ahead of print.
417. Houghton LA, Gao S, Gilbert SA, Coffin B, Simren M, Gale JD; A4451007 study investigators. Clinical Trial: Study to Investigate the Efficacy and Safety of the Alpha-2-Delta Ligand PD-217,014 in Patients With Irritable Bowel Syndrome. *Aliment Pharmacol Ther.* 2025 Jan 15. Online ahead of print.
418. Burton-Murray H, Guadagnoli L, Kamp K, Trindade IA, Powell LH, Simrén M, Ljótsson B, Keefer L. Rome Foundation Working Team Report: Consensus Statement on the Design and Conduct of Behavioural Clinical Trials for Disorders of Gut-Brain Interaction. *Aliment Pharmacol Ther.* 2025 Jan 21. Online ahead of print.
419. Barbara G, Aziz I, Ballou S, Chang L, Ford AC, Fukudo S, Nurko S, Olano C, Saps M, Sayuk G, Siah KTH, Van Oudenhove L, Simrén M. Rome Foundation Working Team Report on overlap in disorders of gut-brain interaction. *Nat Rev Gastroenterol Hepatol.* 2025 Jan 27. Online ahead of print.

Editorials

1. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Feb): 1-2
2. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Mar): 1-2
3. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Apr): 1-2
4. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (May): 1-2
5. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Jun): 1-2
6. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Jul): i-ii
7. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Aug): i-ii
8. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Sep): i-ii
9. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Oct): i-ii
10. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Nov): i-ii
11. Spiller R, Simrén M. Gut Digest. *Gut* 2008; 57 (Dec): i-ii
12. Spiller R, Simrén M. Gut Digest. *Gut* 2009; 58 (Jan): i-ii
13. Spiller R, Simrén M. Gut Digest. *Gut* 2009; 58 (Feb): i-ii
14. Spiller R, Simrén M. Gut Digest. *Gut* 2009; 58 (Mar): i-ii
15. Spiller R, Simrén M. Gut Digest. *Gut* 2009; 58 (Apr): i-ii
16. Spiller R, Simrén M. Gut Digest. *Gut* 2009; 58 (May): i-ii
17. Spiller R, Simrén M. Gut Digest. *Gut* 2009; 58 (Jun): i-ii
18. Simrén M, Farrugia G, Mawe G. The places to be for neurogastroenterologists. *Neurogastroenterol Motil.* 2012 Jun;24(6):501-2.
19. Farrugia G, Simren M, Mawe G. Introducing our Associates. *Neurogastroenterol Motil.* 2013 Apr;25(4):277

20. Farrugia G, Mawe G, Simren M, Bradesi S, Bredenoord A. Neurogastroenterology and motility's impact factor. *Neurogastroenterol Motil.* 2013 Oct;25(10):779.
21. Farrugia G, Simren M, Mawe G, Bradesi S, Bredenoord AJ. Gut microbiota and neurogastroenterology and motility: the good the bad and the ugly. *Neurogastroenterol Motil.* 2014 Mar;26(3):295.
22. Simrén M. UEG Week Vienna 2014: New horizons, fresh ideas. *United European Gastroenterol J.* 2013 Oct;1(5):403-4
23. Simrén M. UEG Week in Vienna 2016-advancing science, linking people. *United European Gastroenterol J.* 2015 Oct;3(5):484.
24. Simrén M. Reflecting on a memorable UEG Week 2015.... *United European Gastroenterol J.* 2015 Dec;3(6):572.
25. Bredenoord AJ, Browning KN, Mawe GM, Galligan JJ, Simren M. News from the editors of *Neurogastroenterology and Motility*. *Neurogastroenterol Motil.* 2016 Oct;28(10):1451
26. Ianiro G, Simren M. How to get your work published: Tricks and pearls. *United European Gastroenterol J.* 2017 Mar;5(2):300-301.

Thesis

Simrén M. Irritable bowel syndrome. Pathophysiological and clinical aspects. University of Göteborg. 2001.

Books / book chapter

- Simrén M. IBS - Irriterande för patient och doktor... Hässle läkemedel AB. 2002
- Simrén M. Stress och symptom från magtarmkanalen. in "Stress - individen, organisationen, samhället, molekylerna" Rolf Ekman o Bengt Arnetz (red); Liber 2005; 2013.
- Simrén M. Irritable bowel syndrome in "Medicinska mag-tarmsjukdomar" Henry Nyhlin (red); Studentlitteratur 2008
- Ass. Editor of Hultcrantz R et al "Gastroenterologi & Hepatologi" - Liber; 2011
- Editor Simrén M et al "Gastroenterologi & Hepatologi" - Liber; 2022
- Simrén M: "Förstoppning", "Illumäende och kräkning", "Funktionella mag-tarmsjukdomar – generella aspekter", "Funktionella esofagussjukdomar", "Motilitetsstörningar i esofagus och ventrikeln" in Hultcrantz R et al: "Gastroenterologi & Hepatologi" - Liber; 2011
- Simrén M: "Förstoppning", "Illumäende och kräkning", "Dyspepsi", "Funktionella mag-tarmsjukdomar – generella aspekter", "Funktionella esofagussjukdomar", "Motilitetsstörningar i esofagus och ventrikeln" in Simrén M et al: "Gastroenterologi & Hepatologi" - Liber; 2023
- "Digestionskanalens sjukdomar" with Stefan Lindgren in Lindgren S et al "Medicin" - Studentlitteratur; 2011, 2017.
- Editor of Simrén M et al, "Medicin" – Studentlitteratur 2025
- "Digestionskanalens sjukdomar" with Klas Sjöberg Stefan Lindgren in Simrén M et al "Medicin" - Studentlitteratur; 2025.
- eBook: "Clinical Insights: IBS" 2013 (Future Science) – editor with Hans Törnblom
- "Sequencing the treatments" with Hans Törnblom in A Emmanuel and E Quigley "Irritable bowel syndrome: Diagnosis and clinical management" – Wiley and Blackwell 2014.
- "Fysiologiska Undersökningsmetoder" in Henry Nyhlin & Greger Lindberg "Magtarmsjukdomar" – Studentlitteratur 2016.
- Läkemedelsboken - Sjukdomar i matstrupe, magsäck och tolvfingertarm - Lars Agréus & Magnus Simrén – 2016
- Simrén M, Whitehead WE. "Alteraciones sensitivomotoras digestivas en el síndrome del intestino irritable" in Clínicas Iberoamericanas de Gastroenterología y Hepatología: "Síndrome del intestino irritable". Pages 43-66 Editors F. Mearin & J. Serra. Elsevier June 2016 ISBN: 978-84-9022-966-8

- Bowel Disorders - Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. In "Rome IV. Functional Gastrointestinal Disorders. Disorders of Gut-Brain Interaction"; Fourth Edition, Volume II. Editors: D. Drossman et al. 2016
- Centrally Mediated Disorders of Gastrointestinal Pain - Whorwell PJ, Keefer L, Drossman DA, Guthrie E, Simrén M, Tillisch K, Olden K. In "Rome IV. Functional Gastrointestinal Disorders. Disorders of Gut-Brain Interaction"; Fourth Edition, Volume II. Editors: D. Drossman et al. 2016
- "Functional bowel disorders (IBS and non-IBS): hypnosis." with Perjohan Lindfors and Jenny Lövdahl, in "Functional Gastrointestinal Disorders. A Biopsychosocial Approach.", edited by Simon R Knowles, Julian Stern and Geoff Hebbard. Routledge 2018

Göteborg 2025-01-28



Magnus Simrén